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Understanding	 the	 transcriptional	 mechanisms	 that	 control	 hematopoiesis	 and	 the	
interaction	 between	 hematopoietic	 stem	 cells	 and	 the	 bone	 marrow	 (BM)	
microenvironment	in	vivo	is	of	considerable	interest.	
	The	 calcineurin‐dependent	 transcription	 factor	 NFAT	 (Nuclear	 Factor	 of	 Activated	 T	
cells)	 is	 known	 as	 master	 regulator	 of	 cytokine	 production	 in	 T	 lymphocytes	 and	




internal	 calcium	 concentration	 within	 an	 external	 stimuli	 leads	 to	 activation	 of	 the	
calcium‐dependent	 calcineurin,	 followed	 by	 dephosphorylation	 and	 nuclear	
translocation	of	NFAT.		
We	have	previously	shown	that	NFATc2,	a	member	of	the	NFAT	family,	is	expressed	in	
CD34+	 hematopoietic	 stem	 cells	 (HSC).	 A	 mouse	 model	 harboring	 NFATc2	 deficiency	
provides	 the	 opportunity	 for	 in	 vivo	 investigation	 of	 the	 role	 of	 NFATc2	 in	
hematopoiesis.		
Our	recent	observations	showed	that	aged	mice	lacking	the	transcription	factor	NFATc2	
develop	 peripheral	 blood	 anemia	 and	 thrombocytopenia,	 BM	 hypoplasia	 and	
extramedullary	hematopoiesis	in	spleen	and	liver.	The	proliferation	and	differentiation	
of	NFATc2‐deficient	hematopoietic	stem	cells	ex	vivo,	however,	was	found	to	be	intact.	It	
remained	 therefore	unclear	whether	 the	disturbed	hematopoiesis	 in	NFATc2‐deficient	
mice	 was	 caused	 by	 the	 hematopoietic	 or	 the	 stroma	 component	 of	 the	 BM	
hematopoietic	niche.		
In	the	current	study	we	dissected	the	relative	contribution	of	hematopoietic	and	stroma	
cells	 to	 the	 phenotype	 of	 the	 NFATc2‐deficent	 mice	 by	 transplanting	 immuno‐
magnetically	purified	NFATc2‐deficient	(KO)	HSCs	to	lethally	irradiated	wild	type	(WT)	
mice,	 and	 vice	 versa.	 After	 a	 post‐transplantation	 period	 of	 6‐8	 months,	 peripheral	







Transplantation	 of	 NFATc2‐deficient	 HSCs	 into	 WT	 recipients	 (KOWT)	 induced	
similar	hematological	abnormalities	as	those	occurring	in	non‐transplanted	KO	mice	or	
in	KO	mice	 transplanted	with	KO	 cells	 (KOKO).	 Compared	 to	WT	mice	 transplanted	
with	WT	cells	(WTWT),	KOWT	mice	showed	evidence	of	anemia,	thrombocytopenia	
and	 a	 significantly	 reduced	 number	 of	 hematopoietic	 cells	 in	 their	 BM.	 Likewise,	
KOWT	 mice	 developed	 clear	 signs	 of	 extramedullary	 hematopoiesis	 in	 spleen	 and	
liver,	which	was	not	the	case	in	WT		WT	control	animals.		
In	addition	to	the	hematopoietic	abnormalities,	transplantation	of	NFATc2‐deficient	HSC	
also	 induced	 osteogenic	 abnormalities	 such	 as	 BM	 sclerosis	 and	 fibrosis	 in	WT	mice.		
This	 phenomenon	was	 rather	 subtle	 and	 of	 incomplete	 penetrance,	 but	 never	 seen	 in	
mice	transplanted	with	WT	cells.	
These	data	demonstrate	for	the	first	time,	that	the	NFATc2	transcription	factor	directly	
regulates	 the	 intrinsic	 function	 of	 hematopoietic	 stem	 cells	 in	 vivo.	 However,	 the	
transcriptional	targets	for	NFAT	in	these	cells	are	yet	unknown.	
In	addition	 to	hematopoietic	 stem	cells,	NFATc2	has	been	 shown	 to	be	expressed	 in	a	
lineage‐specific	 manner	 during	 myeloid	 differentiation	 and,	 notably,	 is	 maintained	
during	 megakaryopoiesis	 while	 it	 is	 suppressed	 during	 the	 differentiation	 of	
neutrophils.	 Bone	 marrow	 megakaryocytes	 are	 the	 precursors	 of	 peripheral	 blood	
platelets	 and	 therefore	 constitute	 an	 integral	 part	 of	 primary	 hemostasis,	 thrombosis	
and	wound	healing.	The	biological	role	of	NFAT	in	megakaryocytes	is	unknown.	
We	 have	 recently	 shown	 that	 NFATc2	 is	 not	 necessary	 for	 megakaryocytic	
differentiation.	On	the	other	hand,	recent	evidence	suggests	that	NFATc2	is	required	for	
the	transcription	of	specific	megakaryocytic	genes.		
In	 this	 study,	 we	 showed	 that	 activation	 of	 the	 calcineurin/NFAT	 pathway	 in	 either	
primary	 megakaryocytes	 or	 CMK	 megakaryocytic	 cells	 forces	 the	 cells	 to	 go	 into	
apoptosis.	Cell	death	in	megakaryocytes	is	induced	by	treating	the	cells	with	the	calcium	
ionophore	 ionomycin	and	suppressed	by	either	 the	pan‐caspase	 inhibitor	zVAD	or	 the	
calcineurin	 inhibitor	 cyclosporin	 A	 (CsA).	 Ionomycin	 stimulation	 of	 megakaryocytes	
leads	 to	 the	 expression	 of	 Fas	 Ligand	 (FASLG),	 a	 pro‐apoptotic	member	 of	 the	 tumor	
necrosis	factor	superfamily.	Expression	of	FASLG	was	detectable	as	early	as	four	hours	
after	 stimulation	 on	 the	 membrane	 of	 ionomycin‐treated	 megakaryocytes,	 was	






pretreated	 with	 CsA	 or	 expressing	 the	 specific	 peptide	 inhibitor	 of	 NFAT,	 VIVIT.	 To	
investigate	 the	 physiological	 relevance	 of	 FASLG	 expression	 on	 megakaryocytes,	 we	
performed	co‐cultures	of	megakaryocytes	with	Fas‐expressing	T‐lymphocytes,	in	which	
CMK	 cells	 were	 left	 either	 unstimulated	 or	 pre‐stimulated	 with	 ionomycin	 and	 then	
added	 to	 Jurkat	 cells.	 The	 presence	 of	 ionomycin‐stimulated	 CMK	 cells,	 but	 not	 of	
unstimulated	 cells	 or	 cells	 stimulated	 in	 the	 presence	 of	 CsA,	 significantly	 induced	
apoptosis	in	Jurkat	cells.	Overexpression	of	NFATc2	in	CMK	cells	enhanced	their	potency	
to	 induce	 apoptosis	 in	 Jurkat	 cells,	 while	 cells	 expressing	 VIVIT	 were	 less	 effective.	
Apoptosis	induction	of	Jurkat	cells	by	stimulated	CMK	cells	was	partially	blocked	by	the	
presence	of	either	a	neutralizing	antibody	against	FASLG	or	an	antagonistic	antibody	to	
Fas	 during	 the	 co‐culture	 period,	 indicating	 involvement	 of	 the	 FASLG/Fas	 apoptosis	
pathway.				
These	 results	 represent	 the	 first	 clear	 evidence	 for	 a	 biological	 function	 of	 the	





Finally,	 we	 have	 identified	 by	 RNA	 sequencing	 analysis	 of	 NFATc2‐expressing	 and	 ‐
deficient	 cells,	 the	 entire	 set	 of	 genes	 which	 is	 induced	 by	 NFATc2	 in	 stimulated	
megakaryocytes.	 Functional	 pathway	 analysis	 suggests	 an	 involvement	 of	 NFATc2	 in	












Nuclear	 factor	 of	 activated	 T	 cells	 (NFAT)	 is	 primarily	 known	 as	 an	 inducible	
transcription	 factor	 in	 activated	 T	 cells.1	 However,	 isolation	 and	 molecular	
characterization	 of	 NFAT	 family	 members	 revealed	 that,	 despite	 their	 names,	 NFAT	
expression	is	not	restricted	to	T	cells.	In	fact,	NFAT	proteins	have	been	identified	in	cells	
of	non‐immune	system	as	well	 as	 the	other	 cells	of	 the	 immune	system.2‐5	 	Therefore,		
the	role	of	 	NFAT	proteins	was	 investigated	in	the	regulation	of	other	cells	and	tissues	
outside	 of	 the	 immune	 system,	 including	 skeletal	 muscle	 and	 cardiac	 hypertrophy,6‐8	
cardiac	valve	morphogenesis,9‐11	angiogenesis,10,	 12,	 13	bone	tissue	including	osteoblasts	




NFATc4),	 NFAT4	 (also	 known	 as	 NFATc3	 or	 NFATx)	 and	 NFAT5	 (also	 known	 as	
enhancer	binding	protein	TonEBP).	NFAT	family	members	evolutionarily	belong	to	the	
REL‐nuclear	factor‐κB	(REL–NF‐κB)	family	of	transcription	factors.3,	24,	25	NFAT	proteins	
contain	 an	 amino‐terminal	 transactivation	 domain	 (TAD),	 a	 regulatory	 domain	 (also	
known	 as	 the	NFAT	homology	 region,	NHR),	 a	 highly	 conserved	DNA‐binding	 domain	
(also	known	as	the	Rel‐homology	domain,	RHD)	and	a	carboxy	terminal	domain	(figure	













DNA‐binding	 domain	 (also	 REL‐homology	 domain,	 RHD),	 and	 a	 carboxy‐terminal	
domain	 (C‐terminal	 domain).	 The	 regulatory	 domain	 contains	 an	 N‐terminal	










is	 initiated	 when	 cell	 surface	 receptors	 are	 coupled	 to	 Ca2+	 release	 which	 triggers	 a	
process	 that	 leads	 to	 the	 activation	 of	 Ca2+/calmodulin‐dependent	 serine	phosphatase	
calcineurin.2,	 3	 Calcineurin	 is	 essential	 for	 NFAT	 activation	 by	 dephosphorylating	
multiple	 phosphoserines	 in	 the	 regulatory	 domain	 of	 NFAT,	 which	 contributes	 to	 the	
translocation	 of	 NFAT	 to	 the	 nucleus	 where	 it	 mediates	 specific	 transcriptional	
programs.	
NFAT	binds	to	the	promoter	of	a	diversity	of	 inducible	genes	including	those	encoding	














Calcineurin‐NFAT	 signaling	 has	 been	 shown	 to	 interact	 with	 many	 other	 signaling	
pathways	 in	 the	 cell	 which	 indicates	 that	 NFAT	 proteins	 cooperate	 with	 different	
transcription	factors.	
Once	inside	the	nucleus,	NFAT	binds	to	the	promoter	of	its	target	genes.	Since	it	can	also	
function	as	dimeric	 transcription	 factor	 (except	 for	NFAT5),33	NFAT	binds	 to	 the	DNA	
either	 with	 another	 NFAT	 molecule	 (homodimer)	 or	 most	 commonly	 with	 other	
transcription	 factors	 (heterodimer).34	 There	 are	 several	 transcription	 factor	 families	
that	 interact	 with	 NFAT,	 including	 activator	 protein	 1	 (AP1),	 forkhead	 box	 P‐family	
proteins	(such	as	FOXP2	and	FOXP3)	and	proteins	of	MAF	and	GATA	families.4	
In	principle,	 this	ability	to	 interact	with	different	transcriptional	partners	allows	many	






NFAT	 during	 T	 cell	 activation.35	 NFAT‐AP1	 cooperation	 integrates	 several	 signaling	
pathways	 and	 processes,	 namely,	 calcium	 signaling,	 which	 is	 responsible	 for	 the	
activation	 of	 NFAT	 proteins;	 and	 the	 RAS‐MAP	 kinase	 pathway,	 which	 influences	 the	
activation	of	Fos	and	Jun.36‐38	In	the	absence	of	AP1,	NFAT	proteins	have	been	found	to	













activity	 of	 calcineurin	 by	 binding	 to	 calcineurin	 and	 blocking	 its	 phosphatase	 activity.	
These	 inhibitors	 include	 calcineurin‐binding	 protein	 1	 (CABIN1	 or	 CAIN),40	 A‐kinase	
anchor	 protein	 79	 (AKAP79),41,	 42	 the	 members	 of	 the	 calcipressin	 family	 (CSP,	 also	
known	as	modulatory	 calcineurin‐interacting	proteins,	MCIP),	Down	syndrome	critical	
region	 (DSCR)	 proteins	 or	 regulator	 of	 calcineurin	 (RCAN)43	 and	 Calcineurin	
homologous	 protein	 (CHP).44‐46	 As	 specific	 NFAT	 inhibition	 is	 considered	 to	 be	 of	
importance,	 considerable	 effort	 has	 been	 undertaken	 to	 design	 new	 inhibitors	 which	





The	 interest	 in	 NFAT	 proteins	 increased	 by	 the	 observation	 that	 their	 activation	was	
inhibited	 by	 immunosuppressive	 drugs	 such	 as	 cyclosporin	 A	 (CsA)	 and	 tacrolimus	
(FK506).	 These	 pharmacological	 agents	 are	 widely	 used	 in	 the	 treatment	 of	 patients	
undergoing	transplantation	in	order	to	block	NFAT	activation	in	T	cells.24,	48,	49	CsA	and	
FK506	 inactivate	 the	 canonical	 NFAT	 pathway	 by	 targeting	 the	 endogenous	 cytosolic	
proteins,	 cyclophilin	 (Cyp)	 and	FK506	binding	proteins	 (FKBP)	 (collectively	known	as	
the	 immunophilins),	 respectively.50‐52	 The	 CsA/FK506	 immunophilin	 complexes	 then	
bind	 to	 the	 subunits	 of	 calcineurin	 (CnA	 and	 CnB)	 which	 ultimately	 leads	 to	 the	
disruption	of	calcineurin	activity.53,	54	
A	major	 disadvantage	 of	 these	 agents,	 however,	 is	 that	 by	 inhibiting	 calcineurin	 they	












Due	 to	 the	 challenges	 following	 CsA/FK506	 administration,	 there	 was	 an	 attempt	 to	
develop	an	NFAT‐specific	 inhibitor	of	calcineurin	signaling	 that	would	not	affect	other	
calcineurin	substrates.		
Efficient	dephosphorylation	of	NFAT	 in	activated	cells	depends	on	 its	 interaction	with	
calcineurin.	 	 The	 calcineurin	 docking	 site	 in	 the	 regulatory	 domain	 has	 the	 consensus	
sequence	PxIxIT	(where	X	can	be	any	amino	acid),	which	 is	highly	conserved	between	
different	 NFAT	 family	 members.	 Peptides	 binding	 to	 this	 sequence	 are	 able	 to	 block	
NFAT‐calcineurin	interaction	as	well	as	NFAT	activation.	A	high‐affinity	peptide,	VIVIT,	
was	selected	from	a	randomized	peptide	library	and	shown	to	effectively	compete	with	


























Hematopoiesis	 represents	 one	 of	 the	 well‐defined	 systems	 of	 adult	 stem	 cell	
development	where	multipotent	hematopoietic	stem	cells	(HSCs)	give	rise	to	a	range	of	
morphologically	 distinct	 mature	 cell	 types,	 all	 characterized	 by	 their	 unique	 gene	
expression	profiles.59‐61	Throughout	adult	 life,	normal	hematopoiesis	takes	place	in	the	
bone	marrow	(BM).	Schofield	demonstrated	 for	 the	 first	 time	 that	 the	stem	cell	 fate	 is	
determined	 by	 the	 surrounding	 microenvironment.62	 At	 present,	 these	 stem	 cell	
microenvironments	are	referred	to	as	stem	cell	niches.63,	64	Consequently,	in	addition	to	
the	cell	 intrinsic	mechanisms,	HSC	behavior	 is	 in	part	 controlled	by	exogenous	 factors	
provided	by	niche	cells.65	This	crosstalk	between	HSCs	and	the	niche	has	been	found	to	
be	 triggered	 by	 a	 variety	 of	 potential	 regulators	 including	 chemokines,	 cytokines	 and	
growth	 factors	 originating	 from	 the	 cells	 itself	 or	 other	 type	 of	 cells,	 as	 well	 as	
interaction	 with	 the	 neighboring	 cells	 and	 the	 extracellular	 matrix	 (ECM),	 notably,	
CXCL12	(SDF‐1)/CXCR4	and	jagged‐1/notch	signaling.66‐68	
Gene	 expression	 induced	 by	 extrinsic	 signals	 works	 together	 with	 the	 intrinsic	 main	
differentiation	 program.65	 A	 large	 repertoire	 of	 molecules	 ranging	 from	 cell	 surface	
receptors	 to	 signal	 transduction	molecules	and	 transcription	 factors	are	 recognized	as	
intrinsic	regulators.	Because	of	their	essential	roles	in	the	development,	expansion	and	
maintenance	 of	 HSCs,	 transcription	 factors	 have	 attracted	 major	 attention	 among	
intrinsic	factors.69	Identification	and	functional	characterization	of	specific	transcription	
factors	will	not	only	advance	our	understanding	of	normal	regulation	of	hematopoiesis	
but	 also	 widen	 our	 prospect	 of	 how	 transcriptional	 regulation	 leads	 to	 diseases	 and	
cancer.	
To	date,	a	number	of	 transcription	 factors	have	been	 identified	which	specify	whether	
HSCs	 remain	 in	 an	 undifferentiated	 state	 or	 differentiate	 along	myeloid,	 lymphoid,	 or	
erythro‐megakaryocytic	lineages.70	For	example,	the	transcription	factors	Runx1	and	Scl	
(Tal1)	were	 found	 to	be	 important	 to	retain	repopulating	activity	and	multipotency	of	



















the	 proliferation	 and	 differentiation	 of	 hematopoietic	 cells.76	 A	 wide	 variety	 of	
transcription	factors	(as	mentioned	above)	has	been	identified	as	being	critical	for	HSC	
regulation.	Boer	et	al.	suggested	that	NFAT	is	the	regulator	of	various	cytokines,	which	







In	 a	 study	of	Kiani	 et	 al,	 the	 gene	 expression	pattern	of	 each	NFAT	 family	member	 in	
CD34+	 hematopoietic	 stem	 cells	 and	 during	 their	 lineage	 commitment	 to	 various	
hematologic	 cell	 types	 (i.e.,	 eosinophil,	 neutrophil,	 erythroid,	 or	 megakaryocytic	
lineages)	was	 established.	 Subsequent	 results	 showed	 that	NFAT	expression	 follows	 a	
lineage‐	 and	 partly	 also	 family	 member‐specific	 pattern	 during	 myeloid	
differentiation,78,	79	showing	that	NFATc2	protein	is	not	expressed	in	mature	neutrophils	
and	 monocytes.	 Eosinophils	 express	 NFATc1,	 c2	 and	 c3,80‐82	 whereas	 mature	














2.2.2	 HSC	 transplantation:	 A	 tool	 to	 investigate	 the	 regulation	 of	
hematopoiesis					
	
Hematopoiesis	 occurs	 in	 the	 BM	 and	 in	 close	 contact	with	 BM	 stroma	 cells.63,	 85,	 86	 A	
number	 of	 interactions	 and	 signaling	 pathways	 maintain	 the	 intimate	 association	 of	
HSCs	 and	 marrow	 stroma	 cells.	 An	 increasing	 number	 of	 studies	 is	 focused	 on	 the	
influence	of	the	niche	on	viability,	proliferation	and	differentiation	of	HSCs.	Yet,	there	is	








Hematopoietic	 stem	 cell	 transplantation	 (HSCT)	 is	 a	 medical	 approach	 used	 in	
conjugation	 with	 high	 dose	 chemotherapy	 and/or	 irradiation	 for	 the	 treatment	 of	
aberrant	hematopoiesis	resulting	from	intrinsic	marrow	defects.89,	90	 	This	may	emerge	
from	 a	 lack	 or	 malfunction	 of	 either	 extrinsic	 or	 intrinsic	 factors	 involved	 in	
hematopoiesis	(for	details	see	section	2.2).	Therefore,	HSC	transplantation	experiments	
are	 an	 adequate	 approach	 to	 fully	 explore	HSC	 functions	 and	 interactions	 in	vivo.91,	 92	
The	 standard	approach	 in	both	patients	and	experimental	 animals	 is	 to	 inject	 isolated	
HSCs	 intravenously.93	 In	 this	process,	HSCs	 find	their	way	to	the	host's	BM	niche	via	a	
mechanism	 referred	 to	 as	 'homing'.94	 Transplantation	 chimera	 studies	 in	 transgenic	
models,	in	which	either	the	host	or	the	donor	harbor	a	genetic	defect,	may	facilitate	the	















have	 redundant	 functions	 in	 the	 cell,	 recent	 studies	 on	 mice	 lacking	 NFAT	 family	
members	suggest	that	they	play	distinct	roles	in	the	regulation	of	cell	activities.31,	32,	98	
NFATc2‐/‐	mice	display	a	 lymphocyte	hyperproliferative	phenotype	with	an	increase	in	
the	 size	 of	 peripheral	 lymphoid	 organs,	 typically	 accompanied	 by	 a	 consistently	
enhanced	T	helper	type	2	immune	response,	a	reduction	in	programmed	cell	death	and	









An	 increasing	 number	 of	 evidence	 suggests	 that	 NFAT	 transcription	 factors	 are	
associated	 with	 gene	 expression	 in	 a	 variety	 of	 cell	 types.	 In	 addition	 to	 lymphocyte	
hyperproliferation,	the	absence	of	NFATc2	 in	vivo	 leads	to	alterations	in	the	regulation	
of	cell	cycle,	most	 likely	due	to	an	 increase	 in	the	expression	of	cyclins.31,	 97	Moreover,	
lack	 of	 NFATc2	 causes	 an	 uncontrolled	 growth	 of	 cartilage	 and	 skeletal	 muscle	 cells	
implying	a	suppressor	role	for	NFATc2	in	these	cells.18,	104	Others	also	demonstrated	that	
NFATc2	deficiency	 leads	 to	 articular	 cartilage	degradation	probably	due	 to	 the	 loss	of	
type‐II	collagen	(collagen‐2)	in	articular	chondrocytes.105		
In	 our	 previous	 study	 on	 aged	 NFATc2‐deficient	mice	 (>12	months	 old)	we	 reported	
that	these	mice	develop	anemia,	thrombocytopenia,	and	lymphocytosis.	Lack	of	NFATc2	
in	these	mice	leads	to	BM	hypoplasia	with	a	remarkable	loss	of	blood	cells	of	erythroid,	
granulocytic,	 and	megakaryocytic	 lineages,	 while	 the	 differentiation	 potential	 of	 their	
progenitors	remains	intact.	Moreover,	as	reflected	by	the	presence	of	bone	trabeculae	as	
well	as	reticular	fibers	in	the	marrow	cavity,	these	mice	display	osteomyelosclerosis	(in	
some	cases	osteomyelofibrosis	or	myelofibrosis).	Also,	 the	 spleen	of	NFATc2‐/‐	mice	 is	











Megakaryocytes	 (MKs),	 a	 small	 population	 (<0.5%)	 of	 BM	 cells,	 arise	 from	






blood	 platelets.	 They	 therefore	 represent	 an	 integral	 part	 of	 primary	 hemostasis,	
thrombosis	and	wound	healing.107,	108	MKs	have	been	characterized	as	the	largest	cell	of	
the	BM	with	a	multilobed	and	polyploid	nucleus.		
MKs	 undergo	 a	 differentiation	 process,	 known	 as	 "megakaryopoiesis",	 in	 which	
multipotent	HSCs	 convert	 to	 committed	megakaryocyte‐erythroid	 precursors	 (MEP	 in	
figure	 2.2),75	 colony	 forming	 unit	 megakaryocytes	 (CFU‐MK)	 and	 immature	 MKs	 or	
megakaryoblasts,	 respectively.	 CFU‐MK	 are	 considered	 the	 first	 stage	 of	
megakaryopoiesis	 that	 shows	 distinct	 megakaryocyte‐lineage	 surface	 markers.109	




megakaryopoiesis,	 thrombopoietin	 (TPO)	 has	 been	 demonstrated	 as	 the	 major	
physiological	factor	for	megakaryocyte	lineage	development.113‐118	In	spite	of	TPO	which	
is	 essential	 for	 the	 whole	 process	 of	 megakaryopoiesis,	 other	 cytokines	 including	
interleukin‐3	(IL‐3),	granulocyte	colony‐stimulating	factor	(G‐CSF)	and	GM‐CSF	act	only	
on	early	stages	of	megakaryopoiesis.119,	120	
Increasing	 evidence	 suggests	 that	MKs	may	 serve	 an	 additional,	 cell‐intrinsic	 function	
that	extends	beyond	their	role	as	platelet	producers.	 In	addition	to	their	main	location	
(BM),	 MKs	 can	 also	 be	 found	 in	 spleen,	 lung,	 liver,	 cord	 blood	 (CB)	 and	 mobilized	
peripheral	 blood	 (MPB)	 under	 certain	 conditions	 of	 stress,	 inflammation	 and	 organ	
damage.121‐124	MKs	dysfunction	has	been	implicated	in	the	induction	of	several	myeloid	
disorders	such	as	myelodysplastic	syndrome	(MDS)	and	chronic	myelogenous	leukemia	
in	 which	 the	 number	 of	 small	 hypolobulated	 MKs	 is	 increased	 in	 the	 BM.	 Excess	
production	of	cytokines	and	growth	factors	(namely	TGF‐ß)	by	MKs	has	been	shown	to	



















Fli‐1	 and	Ets‐1	 has	 been	 reported	 as	 a	 positive	 regulator	 of	megakaryopoiesis.129	 The	
activation	 of	 Fli‐1	 results	 in	 increased	 expression	 of	 megakaryocyte‐specific	 genes,	
namely	genes	related	to	megakaryocytic	phenotype	markers	such	as	CD41	and	CD61.112		
Fli‐1	deficiency	in	mice	results	in	impaired	megakaryopoiesis	and	thrombocytopenia.128,	
130	 Fli‐1	 is	 involved	 in	 the	 interaction	 of	 GATA‐1	 and	 friend	 of	 GATA‐1	 (FOG‐1),	 two	
transcription	 factors	which	 are	 important	 for	many	 stages	 of	megakaryopoiesis.131‐133	
GATA‐1	 knockout	 mice	 harbor	 thrombocytopenia	 and	 a	 delay	 in	 megakaryocytic	
development.134	In	other	studies,	GATA‐1	has	been	introduced	as	a	negative	regulator	of	























As	 described	 in	 section	 2.3,	 aged	 mice	 lacking	 NFATc2	 harbor	 thrombocytopenia.	 In	
addition,	MKs	 have	 been	 implicated	 to	 have	 a	 primary	 role	 in	myelofibrosis,	which	 is	
observed	in	aged	NFATc2‐/‐	mice.		The	investigation	by	Kiani	et	al.	demonstrated	for	the	
first	 time	 that	 the	 expression	 of	 NFAT	 family	 member	 c2	 is	 maintained	 or	 even	
upregulated	 during	 megakaryopoiesis.79	 Subsequent	 studies	 suggested	 that	
calcineurin/NFAT	 activation	 is	 dispensable	 for	 effective	 megakaryopoiesis,	 but	
contributes	to	MK	function	by	regulating	the	expression	of	a	number	of	megakaryocytic	
genes	e.g.	FASLG,	RCAN1	and	CD40LG.79,	126,	142,	143	FASLG,	a	known	NFATc2	target	in	T	





FASLG,	 a	 proapoptotic	 member	 of	 the	 tumor	 necrosis	 factor	 superfamily,	 has	 been	
established	as	an	NFAT	target	in	T	cells.28,	144,	145	The	membrane‐bound	FASLG	is	cleaved	
by	 an	 external	 matrix	 metalloproteinase	 (namely,	 MMP‐7)	 and	 generates	 the	 soluble	
version	 (sFASLG),	 which	 is	 found	 to	 be	 less	 efficient	 in	 inducing	 apoptosis	 in	 target	
cells.146	Expression	of	functional	FASLG	by	activated	T	cells	and	natural	killer	(NK)	cells	
plays	 a	 key	 role	 in	 eliminating	 T	 cell	 populations	 following	 antigenic	 stimulation	 and	
clonal	 proliferation.147,	 148	 On	 the	 other	 hand,	 FASLG	 expression	 by	 cells	 of	 immune‐






in	 the	 activation	 of	 a	 death	 signaling	 cascade	 and	 the	 induction	 of	 apoptosis	 in	 Fas‐






hematopoietic	 cells	 and	 lymphocytes),151	 but	 the	 expression	 of	 its	 ligand	 (FALSG)	 is	
more	restricted.		
Apoptosis,	 an	 evolutionary	 conserved	 biological	 process,	 also	 known	 as	 type	 I	
programmed	cell	death,	plays	a	critical	role	in	physiological	and	pathological	processes.	
Apoptosis	is	characterized	by	a	diverse	range	of	structural	alterations	in	cells,	including	
blebbing	 of	 plasma	membrane,	 nucleus	 condensation,	 DNA	 fragmentation,	 cleavage	 of	
some	cellular	proteins,	cytochrome	c	release	from	mitochondria	and	decreased	caspase	
activation.152‐154	 Disturbance	 of	 apoptosis	 pathways	 (e.g.,	 in	 death	 receptor	 and	










analysis	 purposes,	 the	 next‐generation	 sequencing	 (NGS)	 methods	 are	 rapidly	
progressing.	 NGS	 technologies	 that	 measure	 genome‐wide	 transcription	 levels	 are	
termed	 as	mRNA	 sequencing	 (RNA‐Seq)	which	 have	 clear	 advantages	 over	 previously	
applied	 gene	 expression	 technologies.157‐160	 In	 fact,	 RNA‐Seq	 provides	 much	 greater	
sensitivity	 and	 a	 more	 accurate	 estimation	 of	 absolute	 expression	 levels	 than	
microarrays	 and	 allows	 studying	 the	 events	 which	 are	 beyond	 the	 reach	 of	
microarrays.161‐163	
In	 principle,	 isolated	 total	 RNA	 is	 copied	 to	 complementary	 DNA	 (cDNA)	 and	 cut	 at	
random	 positions.	 Fragments	 with	 a	 certain	 size	 are	 selected	 for	 amplification	 with	
polymerase	chain	reaction	(PCR).	Next,	the	amplified	cDNA	is	sequenced	by	NGS	method	









order	 to	 process	 these	 intensive	 computational	 steps,	 however,	 powerful	 servers	 and	
bioinformatics	skills	are	required.160	
Although	 novel	 NGS	 methods	 in	 terms	 of	 procedure,	 technique	 and	 accuracy	 vary	
considerably	 in	comparison	to	microarray	 technologies,	 the	principles	of	experimental	
design	are	similar.159	One	approach	that	ensures	a	successful	gene	expression	study	 is	
the	 application	of	 replicates.	 	 In	particular,	 biological	 replicates	 (“true”	 replicates)	 are	
desirable	 as	 they	 indicate	 the	 variation	 among	 biological	 samples.	 When	 the	 same	
biological	 sample	 is	measured	 repeatedly	 (normally	 ≥	 three	 times),	 the	 replicates	 are	
termed	 “technical”	 replicates.	 Hence,	 a	 careful	 design	 is	 essential	 to	 distinguish	
































studies	 on	 mice	 lacking	 NFATc2	 demonstrated	 hematological	 and	 osteological	
abnormalities.	The	role	of	NFATc2	in	hematopoiesis	and	the	respective	contribution	of	






potentially	 are	 caused	 by	 megakaryocyte	 dysfunction.	 Moreover,	 NFATc2	 has	 been	
shown	 to	 be	 upregulated	 during	 megakaryocyte	 differentiation,	 though	
megakaryopoiesis	 proved	 to	 occur	 normally	 in	 the	 absence	 of	NFATc2.	 Therefore,	we	
sought	 to	 investigate	 whether	 the	 calcineurin/NFAT	 pathway	 is	 involved	 in	 the	
regulation	of	gene	expression	in	mature	megakaryocytes.	
	
a)	 Fas	 Ligand,	 a	 proapoptotic	 member	 of	 the	 TNF‐superfamily,	 has	 been	 previously	
identified	by	our	group	as	an	NFATc2	 transcriptional	 target	 in	megakaryocytes	on	 the	
mRNA	 level.	 In	 this	 study	 we	 aimed	 to	 extend	 these	 findings	 and,	 in	 particular,	 to	
advance	them	to	a	functional	level.	
	





















































































































































 biotinylated	 	 lineage	Ab	cocktail	


































































The	 Meg‐01,	 CMK	 and	 Jurkat	 cell	 lines	 were	 obtained	 from	 the	 German	 collection	 of	





CD34+	 cells	 were	 isolated	 by	 immunomagnetic	 selection	 from	 peripheral	 blood	 of	
granulocyte	 colony‐stimulating	 factor‐(G‐CSF‐)	 mobilized	 healthy	 stem	 cell	 donors,	
using	CD34	MicroBead	kit,	according	to	instructions	provided	by	the	manufacturer.	The	
purities	of	the	resulting	CD34+	populations	were	assessed	by	fluorescence‐activated	cell	
sorting	 (FACS)	 and	 routinely	 exceeded	 95%.	 The	 study	 was	 approved	 by	 the	































specific	 antibodies	 (CD5,	 CD45R,	 CD11b,	 Gr‐1	 and	 Ter‐119),	 followed	 by	 anti‐biotin	
MicroBeads,	according	to	the	manufacturer's	instructions	(mouse	lineage	depletion	kit).	
Lineage‐negative	 enriched	 cells	were	 resuspended	 in	 DMEM	 supplemented	with	 10%	




and	 overlaid	 on	 a	 two‐step	 BSA	 gradient	 (1.5%	 and	 3%)	with	minimal	 agitation	 and	
were	incubated	for	30‐45	minutes	at	room	temperature.	The	cells	sedimenting	through	
the	 lower	 BSA	 gradient	was	 observed	 by	 eyes	 (see	 figure	 5.15).	When	 the	 pellet	was	
formed,	the	upper	phase	(almost	all	liquid	above	the	formed	pellet)	was	removed	gently.	











a	 Shandon	 Cytospin	 slide	 (Thermo	 Fisher	 Scientific	 GmbH,	 Dreieich,	 Germany)		
according	 to	 the	 standard	 cytospin	protocol.	 Samples	were	 air‐dried	 and	 stained	with	





Co‐culture  of  human megakaryocytic  cells  and  Jurkat  T  cells  for  apoptosis 
experiments 




twice	 with	 PBS	 to	 remove	 the	 stimulus.	 The	 cells	 were	 then	 mixed	 with	 Jurkat	 cells	
(targets)	in	an	effector‐to‐target	ratio	(E:T)	of	10:1.	In	selected	experiments,	neutralizing	
antibodies	 against	 Fas	 (ZB4)	 or	 FASLG	 (NOK‐1)	 were	 added	 at	 a	 concentration	 of	
1µg/ml	and	5µg/ml,	respectively,	during	the	co‐culture.	After	20	hours	of	co‐incubation,	
the	cells	were	harvested,	stained	with	annexin	V/	7AAD,	and	the	apoptosis	rate	of	 the	
Jurkat	 cells	 were	 analyzed	 by	 flow	 cytometry.	 CFSE	 was	 used	 to	 gate	 out	 the	 CMK	
effector	 cells	 (see	 figure	 5.14).	 As	 positive	 control,	 Jurkat	 cell	 mono‐cultures	 were	






















by	means	of	 a	23‐gauge	needle.	Cell	 suspensions	were	passed	 through	a	70	µm	nylon	
mesh	cell	strainer	to	obtain	single	cell	suspensions.	Afterwards,	the	cells	were	incubated	
with	 a	 biotin‐labeled	 antibody	 cocktail	 of	 lineage‐specific	 monoclonal	 antibodies,	
followed	by	anti‐biotin	MicroBeads	as	described	above,	according	to	the	manufacturer's	
instructions.	 Lineage‐negative	 enriched	 cells	 were	 then	 labeled	 with	 Sca‐1	 and	 cKit	
antibodies.	 Lin‐/Sca‐1+/cKit+	 (LSK)	 cells	 were	 isolated	 using	 FACS	 sorter.	 Thirty	




After	 a	 period	 of	 6‐8	months	 post‐transplantation,	 transplanted	mice	were	 sacrificed.	
The	 peripheral	 blood,	 BM	 as	well	 as	 spleen	 and	 liver	 cells	 of	 transplanted	mice	were	
collected	 for	 different	 hematological	 analysis.	 The	 peripheral	 blood	 was	 collected	 by	














Single	 cell	 suspensions	 collected	 from	BM,	 spleen	and	 liver	of	 transplanted	mice	were	
resuspended	 in	 RPMI	 medium	 (supplemented	 with	 10%FCS	 and	 1%	 pen/strep)	 and	
mixed	 with	 methylcellulose‐based	 semisolid	 (MethoCult)	 medium	 according	 to	 the	
instructions	 provided	 by	manufacturer.	 Hematopoietic	 progenitor	 cells	were	 assessed	
by	 the	 number	 of	 burst‐forming	 units‐erythrocytes	 (BFU‐E),	 colony‐forming	 units‐
granulocyte/macrophage	 (CFU‐GM),	 CFU‐granulocyte	 (CFU‐G),	 and	 CFU‐macrophage	
(CFU‐M).		0.1x106		BM	cells,	1x106		splenocytes		and	1x106		liver	cells	were	cultured	for	
12	days	in	1	ml	MethoCult	GF	M3434	(for	CFU‐G,	CFU‐M,	CFU‐GM,	BFU‐E).	The	number	
of	 CFU‐megakaryocytes	 (CFU‐MK)	 was	 determined	 by	 culturing	 2.2x106	 BM	 cells	 or	
11x106	splenocytes	for	10	days	in	1	ml	Megacult	 	medium	containing	collagen	solution	




Bone	marrow	was	 flushed	 from	both	 femora	and	 tibiae.	Cell	 suspensions	were	passed	
through	a	70	µm	nylon	mesh	cell	strainer	to	obtain	single	cell	suspensions.	Afterwards,	
the	 cells	 were	 incubated	 with	 biotin‐labeled	 antibody	 cocktail	 of	 lineage‐specific	
monoclonal	antibodies	(CD5,	CD45R,	CD11b,	Gr‐1	and	Ter‐119),	followed	by	anti‐biotin	
MicroBeads,	according	to	the	manufacturer's	instructions	(mouse	lineage	depletion	kit).	
Lineage‐negative	 enriched	 cells	 were	 labeled	 with	 1	 mM	 CFSE	 in	 accordance	 to	 the	
manufacturer’s	 instructions.	 Cells	 were	 then	 injected	 into	 the	 retro‐orbital	 venous	
sinuses	 of	 3‐months‐old	 C57BL/6	mice	 that	 had	 been	 lethally	 irradiated	 (8	 Gy).	Mice	















40	 µg	 of	 protein	 per	 sample	 was	 extracted	 and	 mixed	 with	 loading	 buffer,	 then	
denatured	 at	 95°C	 for	 5	 minutes.	 Sodium	 dodecyl	 sulfate‐polyacrylamide	 gel	
electrophoresis	 (SDS‐PAGE)	 was	 performed	 according	 to	 standard	 procedures.	 For	
Western	blotting	of	FASLG,	10%	acrylamide	gel	was	used.	The	gel	was	run	with	20	mA	
constant	 current.	 The	 separated	 proteins	 were	 transferred	 to	 Hybond‐ECL	
Nitrocellulose	Membrane	(75	mA/gel,	1	h),	and	unspecific	binding	sites	were	blocked	in	
5%	non‐fat	dry	milk	powder	and	0.1%	Tween20	in	PBS	for	1	hour	 in	RT	on	a	shaking	
plate.	Membranes	were	 stained	overnight	with	 antibodies	 to	 FASLG	 (G247‐4)	 (diluted	
1:500)	and	ß‐actin	(1:4000,	as	loading	control),	followed	by	HRP‐conjugated	anti‐mouse	
antibody	 (1:2000)	 after	 3	 times	 	 washing	 for	 5	 minutes	 with	 washing	 buffer	 (0.1%	
Tween20	 in	 PBS)	 to	wash	 away	 unbound	 antibody.	Membranes	were	 then	 developed	





of	 cytospin	 preparations.	 Culture‐derived	 MKs	 were	 mixed	 with	 cytospin	 buffer	 and	
spun	on	round	(Ø 15	mm)	coverslips	according	to	the	standard	cytospin	protocol.	The	
coverslips	were	 further	 processed	 in	 12‐well	 plates	 starting	with	 a	 paraformaldehyde	
(3%)	 fixation	 step.	 After	 removing	 the	 fixative	 reagent,	MKs	were	washed	 twice	with	
washing	 solution	 containing	 0.5%	 Nonidet	 P‐40	 for	 cell	 permeabilization	 and	 0.01%	
sodium	azide	(NaN3)	as	a	preservative	in	PBS.	After	samples	were	blocked	by	10%	FCS	
added	 to	 washing	 solution,	 FASLG	 primary	 antibody	 was	 diluted	 (1:200)	 in	 blocking	








were	 counterstained	 with	 DAPI	 (diluted	 1:2500).	 Cytospins	 were	 then	 mounted	 in	
ProLong	 Gold	 anti‐fade	 reagent	 and	 analyzed	 and	 photographed	 with	 a	 Nikon	






with	PBS,	and	 incubated	on	 ice	 for	30	minutes	with	streptavidin	(1:100	diluted).	After	
two	 final	 washes,	 the	 cells	 were	 resuspended	 in	 PBS	 and	 analyzed	 on	 FACSCalibur	
Cellquest	 software.	 In	 apoptosis	 experiments,	 apoptotic	 cells	 were	 quantified	 by	
assessing	the	membrane	phosphatidylserine	exposure	of	the	cells	using	double‐staining	









h	 and	 then	 were	 decalcified	 in	 Osteosoft.	 Following	 dehydration	 with	 an	 ascending	
ethanol	 series	 and	 xylol,	 the	 tissues	 were	 embedded	 in	 paraffin.	 The	 sections	 were	









All	 procedures	 were	 performed	 exactly	 according	 to	 the	 protocol	 provided	 by	 the	
manufacturer	 (Megacult‐C).	 Briefly,	 the	 slides	 containing	 CFU‐MK	 were	 fixed	 in	 cold	
acetone	 and	 allowed	 to	 air	 dry.	 Acetylcholinesterase	 substrate	 solution	was	 prepared	
freshly	(acetylthiocholiniodide	was	dissolved	in	sodium	phosphate	buffer,	then	sodium	
citrate,	copper	sulfate	and	potassium	ferricyanide	were	added).	Slides	were	incubated	in	
the	 staining	 solution	 for	 4	 hours	 and	 then	were	 fixed	with	 95%	 ethanol,	 rinsed	with	











µMACS	 mRNA	 isolation	 kit	 according	 to	 the	 manufacturer’s	 instructions,	 followed	 by	
DNase	treatment	and	mRNA	purification	using	Agencourt	RNAclean	XP‐beads.	After	first	
and	 second	 strand	 cDNA	 synthesis,	 End‐pair	 and	 A‐tailing	 of	 double	 stranded	 cDNA	
were	 performed	 according	 to	 the	 manufacturer's	 instructions.	 After	 adaptor	 ligation,	
large	 scale	 amplification	 of	 library	 constructs	 was	 performed.	 Thereafter,	 cDNA	 was	
size‐selected	 on	 2%	 agarose	 (E‐Gel)	 and	 the	 libraries	 were	 quantified	 using	 Qubit	











transcriptome)	 using	 BWA	 (http://bio‐bwa.sourceforge.net/bwa.shtml).	 Counts	 per	
gene	were	computed	based	on	the	Ensembl	61	annotation	for	mm9.	The	counts	per	gene	





































is	 highly	 expressed	 in	 hematopoietic	 stem	 cells	 and	 regulated	 during	 myeloid	
commitment	in	a	lineage‐specific	manner.79,	143	
In	 a	 further	 recent	 study	 we	 showed	 that	 aged	 mice	 lacking	 NFATc2	 develop	
hematological	 and	 osteological	 abnormalities	 such	 as	 anemia	 and	 thrombocytopenia,	
BM	 hypoplasia	 (with	 megakaryocytic	 and	 erythroid	 lineages	 being	 most	 affected),	
ossification	 of	 the	BM	 space,	 as	well	 as	 an	 increased	 formation	 of	 reticular	 fibers	 and	
extramedullary	hematopoiesis	in	the	spleen	and	liver.	
	The	 phenotype	 of	 these	 mice	 suggested	 that	 the	 lack	 of	 NFATc2	 apparently	 affects	
either	hematopoietic	cells	or	cells	of	their	microenvironment,	or	the	interaction	of	these	
two	 compartments.	 Whether	 these	 abnormalities	 result	 from	 defects	 in	 the	
hematopoietic	stem	and/or	progenitor	cells	or	 from	BM	stroma	malfunctioning	 in	 this	
study	remained	open.	In	order	to	find	out	the	relative	contribution	of	hematopoietic	and	
stromal	 cells	 to	 the	 phenotype	 of	 the	 NFATc2‐deficient	 mice,	 we	 designed	 a	
transplantation	study	in	which	functional	HSCs	were	isolated	based	on	their	phenotype.	
HSCs	 are	 characterized	 by	 the	 lack	 of	 expression	 of	 a	 number	 of	 cell	 surface	markers	
which	 are	 normally	 found	 on	 differentiating	 or	 mature	 blood	 cells	 (Lin‐,	 lineage	
negative)	while	displaying	high	 levels	of	 Sca1	and	 c‐kit.166,	 167	 	 	 This	population	of	BM	
cells	 is	referred	to	as	the	LSK	compartment	(Lin‐/Sca1+/c‐kit+)	and	has	been	shown	to	
sufficiently	contribute	to	reconstitution	and	repopulation	of	lethally	irradiated	hosts.168		
Thus,	 immunomagnetically‐purified	 NFATc2‐knockout	 (KO)	 LSK	 cells	 (HSCs)	 were	
transplanted	 into	 lethally	 irradiated	wild	type	(WT)	mice,	and	vice	versa.	After	a	post‐
transplantation	 period	 of	 6‐8	 months	 which	 allowed	 the	 phenotype	 to	 develop,	









Figure	5.1.	 Schematic	 representation	of	 the	 transplantation	 study.	Bone	marrow	
cells	were	 flushed	out	of	 femora	and	 tibia	of	WT	and	NFATc2‐/‐	mice.	Lineage	positive	
cells	 were	 depleted	 with	 lineage	 depletion	 kit	 and	 the	 lineage‐negative‐enriched	
population	 of	 the	 cells	was	 labelled	with	 antibodies	 against	 hematopoietic	 progenitor	
markers	 (anti‐Sca1‐PE	and	anti‐cKit‐APC).	Cells	which	were	positive	 for	both	markers	
were	 sorted	 by	 flow	 cytometry	 and	 injected	 into	 lethally	 irradiated	 (8	 Gy)	 WT	 or	
NFATc2‐deficient	 mice.	 After	 a	 post‐transplantation	 period	 of	 6‐8	months,	 peripheral	







In	 order	 to	 evaluate	 the	 impact	 of	 transplantation	 on	 hematopoiesis,	 we	 performed	
complete	blood	 counts	 of	 all	 four	 groups	of	 transplanted	mice	 i.e.,	WTWT,	WTKO	
(WT	HSC	transplanted	into	KO	host),	KOKO	and	KOWT	(KO	HSC	transplanted	into	
WT	host).	The	 results	 (shown	 in	 figure	5.2	and	summarized	 in	 table	5.1)	 showed	 that	
WT	 mice	 transplanted	 by	 HSCs	 from	 NFATc2‐deficient	 mice	 (KOWT)	 were	 anemic	
with	 reductions	 in	 all	parameters	of	 the	erythroid	 lineages,	namely	erythrocyte	 (RBC)	
number,	hemoglobin	(HGB)	and	hematocrit	(HCT)	when	compared	with	those	observed	

















the	 polychromatic	 appearance	 of	 reticulocytes	 (arrows)	 in	 their	 peripheral	 blood	
smears,	resembling	KOKO	controls	(figure	5.2C)		
On	 the	 other	 hand,	 KOWT	 mice	 (compared	 to	 WTWT	 mice)	 showed	 a	 strong	
reduction	in	their	platelet	counts	(figure	5.2	B),	whereas	the	transplantation	of	WT	HSCs	





WTWT	 KOWT KOKO WTKO	
RBC	(1012/L)	 7.32±0.29	 6.15±0.69 5.60±0.49 7.07±0.41	
HGB	(	mmol/L)	 6.58±0.33	 5.67±0.58 4.98±0.43 6.5±0.40	
HCT	(%)	 38.33±1.77	 33.64±2.60 30.65±2.09 36.63±1.51	
PLT	(109/L)	 636.42±89.51 365.42±69.24 473.62±100.11 603.33±106.24	
Reticulocytes	(109/L)	 313.52±37.91 405.14±64.52 513.07±99.09 218.92±51.47	




Neutrophils	 3.7	 2.6 3.2 4.1	
Lymphocytes	 18.3	 24.8 33 22.5	
Monocytes	 0.88	 1.15 1.51 0.94	









Figure	 5.2.	 Anemia,	 thrombocytopenia	 and	 reticulocytosis	 in	 WT	 recipients	
transplanted	 with	 NFATc2‐deficient	 HSCs.	 	 (A)	 Red	 blood	 cell	 parameters	 in	 the	
peripheral	 blood	 of	 transplanted	mice.	 Red	 blood	 cells	 (RBC),	 hemoglobin	 (HGB)	 and	







transplanted	 mice.	 Arrows	 illustrate	 the	 polychromatic	 reticulocytes	 in	 the	 blood	
smears.	n=7	(WTWT),	n=7	(KOWT),	n=8	(KOKO),	n=6	(WTKO).		
	





examined	 the	 BM	 compartments	 of	 transplanted	 mice.	 Transplantation	 of	 NFATc2‐
deficient	 HSCs	 into	WT	 recipients	 (KOWT)	 induced	 BM	 hypoplasia	 (figure	 5.3A)	 in	
comparison	to	WTWT	control	animals,	while	in	KO	mice	transplanted	with	WT	HSCs	
(WTKO),	 total	 BM	 cell	 counts	 were	 significantly	 increased	 compared	 to	 KOKO	
control	 mice	 (figure	 5.3A).	 Cytological	 differentiation	 of	 the	 extracted	 BM	 cells	 of	
KOWT	mice	revealed	that	the	reduction	in	BM	cells	was	most	pronounced	in	erythroid	









stained	 for	 the	 presence	 of	 reticular	 fibers.	 In	 addition	 to	 the	 presence	 of	 bone	











































Figure	5.4.	Decreased	number	 of	 colony‐forming	 cells	 in	WT	mice	 transplanted	
with	NFATc2‐KO	HSCs.	 	Colony‐forming	assays	(CFU‐G,	CFU‐M,	CFU‐GM,	BFU‐E	and	
CFU‐MK)	were	performed	with	BM	cells	of	transplanted	mice.	The	numbers	of	colonies	








5.1.3	 Reciprocal	 transplantation	 experiments:	 effects	 on	 extramedullary	
hematopoiesis.	
Mice	 lacking	 NFATc2	 are	 characterized	 by	 splenomegaly	 and	 extramedullary	
hematopoiesis.84	In	order	to	analyze	extramedullary	hematopoiesis	in	our	transplanted	
model,	we	next	 focused	on	 the	 spleens	and	 livers	of	WT	mice	 transplanted	with	HSCs	
from	NFATc2	deficient	mice	(KOWT).	Enlarged	spleen	as	well	as	a	drastic	increase	in	




relative	 proportion	 of	 erythroid	 and	 megakaryocytic	 cells	 had	 increased	 over	 other	
lineages	(figure	5.5B).	Therefore,	 in	KOWT	mice	(as	well	as	 in	KOKO	controls)	the	
ratio	of	myeloid	to	lymphoid	cells	had	shifted	in	favour	of	the	myeloid	compartment.	
Our	 recent	 study	 on	 the	 steady‐state	 hematopoiesis	 in	NFATc2‐/‐	mice	 suggested	 that	
while	the	frequency	of	hematopoietic	progenitor	cells	is	decreased	in	the	BM	of	KO	mice,	
these	 cells	 preserve	 their	 full	 ability	 to	 differentiate	 along	 the	 erythroid,	 granulocytic,	
and	megakaryocytic	lineages.84	 	We	analyzed	the	frequency	of	myeloid	progenitor	cells	
in	spleen	and	liver	of	transplanted	mice.	Colony	forming	assay	indicated	that	frequencies	
of	 granulocytic/monocytic	 (CFU‐GM/CFU‐G/CFU‐M),	 erythroid	 (BFU‐E)	 and	
megakaryocytic	 (CFU‐MK)	 progenitors	were	 all	 increased	 in	 spleens	 of	 KOWT	mice	
(resembling	 KOKO	 or	 non‐transplanted	 KO	 mice)	 compared	 to	 WTWT	 controls	
(figure	5.5C).		In	contrast,	the	frequency	of	colonies	(granulocytic/monocytic,	erythroid	
and	 megakaryocytic)	 was	 reduced	 in	 WTKO	 mice,	 which	 was	 consistent	 with	 the	
almost	normal	size	of	their	spleens	as	well	as	the	numbers	of	splenocytes,	compared	to	
those	 observed	 in	KOKO	 controls	 (figure	5.5C).	 	 Furthermore,	 colony	 forming	 assay	
results	 from	 the	 liver	 confirmed	 the	 presence	 of	 extramedullary	 hematopoiesis	 in	
KOWT	mice,	as	granulocytic/monocytic	(CFU‐GM/CFU‐G/CFU‐M)	and	erythroid	(BFU‐
E)	 progenitors	were	 increased	 in	 these	mice	 in	 comparison	 to	WTWT	 control	mice	
(figure	4.5D).		
















Figure	 5.5.	 Splenomegaly	 and	 extramedullary	 hematopoiesis	 in	WT	 recipients	
transplanted	 with	 NFATc2‐deficient	 HSCs.	 (A)	 Number	 of	 splenocytes.	 (B)	
Differentials	of	spleen	cells.	Blue,	purple	and	yellow	portion	of	 the	pie	chart	represent	
erythroid,	 granulocytic/monocytic	 and	 lymphocytic	 cells,	 respectively.	 (C)	 Number	 of	








































positive	 cells	 in	 the	 BM	 (B)	 and	 peripheral	 blood	 (C)	 of	 transplanted	mice	 20	 h	 after	
injection.	The	number	of	CFSE+	cells	was	estimated	using	the	same	gate	(here	shown	as	









































It	has	been	well	established	 that,	apart	 from	T	cells,	NFAT	 is	expressed	 in	a	variety	of	
different	 tissues,	 where	 it	 regulates	 the	 expression	 of	 genes	 involved	 in	 cellular	
processes	of	adaptation	and	differentiation.2,	3,	79	
Our	group	has	 recently	established	a	detailed	expression	pattern	of	 all	NFAT	genes	 in	
CD34+	 hematopoietic	 stem	 cells	 and	 during	 their	 differentiation	 into	 various	
hematological	 cell	 types.78,	 79	 This	 phenomenon	 was	 particularly	 evident	 for	 NFATc2,	
which	 in	 megakaryocytic	 cells	 was	 detected	 throughout	 differentiation	 at	 a	 level	
comparable	 to	 T	 cells,	 but	 was	 rapidly	 downregulated	 during	 the	 differentiation	 of	
neutrophils.		
Furthermore,	 NFATc2‐deficient	 mice	 suffer	 from	 thrombocytopenia.	 However,	
subsequent	studies	showed	that	calcineurin/NFAT	activation	is	dispensable	for	effective	






















To	 first	 test	 the	viability	 of	MKs	 in	 cell	 line	models,	megakaryocytic	Meg‐01	and	CMK	





As	shown	 in	 figure	5.7,	 treatment	with	 ionomycin	resulted	 in	a	significant	decrease	of	

























5.2.2	 Activation	 of	 the	 calcineurin	 pathway	 induces	 apoptosis	 in	
megakaryocytes.		
	
Programmed	 cell	 death	 –or	 apoptosis–	 is	 a	 process	 by	 which,	 in	 balance	 with	 cell	
proliferation,	homeostasis	of	a	cell	population	is	maintained.152,	171,	172	
In	 order	 to	 assess	 whether	 the	 reduction	 of	 cell	 viability	 of	 megakaryocytic	 cells	 in	
response	to	ionomycin	was	due	to	the	induction	of	programmed	cell	death,	we	analyzed	
the	 nuclear	 morphology	 of	 untreated	 and	 ionomycin‐treated	 CMK	 cells	 by	
epifluorescence	microscopy	after	nuclear	staining	with	DAPI	(figure	5.8A).	The	analysis	
was	extended	 to	primary	MKs	 (‘culture‐derived	megakaryocytes’)	 (figure	5.8B),	which	





and	 B,	 panels	 i).	 To	 better	 quantify	 the	 pro‐apoptotic	 effect	 of	 ionomycin	 in	
megakaryocytic	 cells,	 we	 used	 the	 flow	 cytometric	 annexin	 V	 assay	 on	 untreated	 and	
ionomycin‐stimulated	 culture‐derived	 primary	 MKs.	 As	 expected,	 within	 24	 h,	
ionomycin	 treatment	resulted	 in	a	significant	 increase	 in	 the	percentage	of	annexin	V‐
positive	MKs,	as	compared	to	unstimulated	controls	(figure	5.8C,	left	and	middle	bars).	
These	results	demonstrate	that	ionomycin	induces	apoptosis	in	megakaryocytic	cells.	




apoptosis,	 confirming	 the	 involvement	 of	 calcineurin	 in	 this	 process	 (figure	 5.8A,	 B,	
panels	iii,	and	figure	5.8C,	right	bar).	Together,	these	data	demonstrate	by	two	different	















Figure	 5.8.	 Activation	 of	 the	 calcineurin	 pathway	 induces	 apoptosis	 in	
megakaryocytes.	(A)	CMK	cells	and	(B)	culture‐derived	primary	MKs	were	either	 left	
untreated	or	stimulated	with	1µM	ionomycin	for	24	h	in	the	presence	or	absence	of	the	
calcineurin	 inhibitor	 cyclosporin	 A	 (CsA).	 Morphological	 changes	 of	 the	 nuclei	 were	
analyzed	by	epifluorescence	microscopy	after	staining	with	DAPI.	Note	the	appearance	
of	 condensed	 chromatin	 (arrows)	 as	 well	 as	 fragmentation	 and	 apoptotic	 bodies	
(arrowheads)	in	the	nuclei	of	ionomycin‐treated	cells	indicating	apoptosis	of	these	cells.	
Scale	 bars	 represent	 10	 µm.	 (C)	 Culture‐derived	 MKs	 were	 either	 left	 untreated	 or	
stimulated	 with	 ionomycin	 for	 24	 h	 in	 the	 presence	 or	 absence	 of	 the	 calcineurin	
inhibitor	 CsA,	 as	 indicated.	 The	 frequency	 of	 apoptotic	 cells	 was	 determined	 by	 flow	
cytometric	 analysis	 of	 annexin	 V‐positive	 cells	 after	 24	 h	 of	 incubation.	 Statistical	
analysis	of	annexin	V‐positive	cells	of	at	 least	 four	 independent	experiments	 is	shown.	
Shown	are	means	±SEM.	*	p	<	0,	05.		
			
5.2.3 Apoptosis induction in megakaryocytes is dependent on NFAT activation 
 
Calcineurin	 is	 the	 key	 enzyme	 for	 NFAT	 activation,	 but	 calcineurin	 has	 also	 other	
substrates	and	affects	various	signaling	pathways	in	addition	to	NFAT.55,	57	To	determine	
if	apoptosis	 induced	by	activation	of	 the	calcineurin	pathway	 in	MKs	was	mediated	by	
NFAT	 or	 by	 other	 substrates,	 CMK	 cells	 were	 retrovirally	 transduced	 with	 either	 an	
NFATc2‐EGFP	 construct	 or	 with	 a	 vector	 encoding	 the	 peptide	 VIVIT‐GFP,	 a	 specific	
inhibitor	of	NFAT	activation.57,	175	NFATc2	was	chosen	out	of	the	NFAT	family	members	
because	 of	 its	 known	 expression	 in	 MKs.78,	 79	 Cells	 transduced	 with	 EGFP	 served	 as	
control.	 Control	 cells	 (CMK‐EGFP),	 cells	 overexpressing	 NFATc2	 (CMK‐NFATc2)	 and	
cells	unable	to	activate	any	NFAT	protein	(CMK‐VIVIT)	were	then	either	 left	untreated	
or	stimulated	with	 ionomycin	 in	 the	presence	or	absence	of	CsA,	and	 further	analyzed	
for	apoptosis	induction	(figure	5.9).	
Microscopic	examination	of	DAPI‐stained	nuclei	revealed	that	overexpression	of	NFATc2	
augmented,	 while	 expression	 of	 VIVIT	 suppressed	 apoptosis	 induction	 in	 CMK	 cells	
(figure	5.9A).	The	effect	of	NFATc2	overexpression	on	apoptosis	was	already	apparent	in	






panel).	We	 confirmed	 these	 results	 by	 evaluating	 the	 apoptosis	 rate	 in	 an	 annexin	 V	
assay	 (figure	 5.9B).	 Ionomycin	 treatment	 significantly	 enhanced	 the	 apoptosis	 rate	 in	
both	 control	 cells	 and	 in	 cells	 overexpressing	NFATc2,	 but	 remained	without	 effect	 in	
CMK‐VIVIT	cells,	which	are	unable	to	activate	NFAT	(figure	5.9B,	white	and	black	bars).	
In	 the	 presence	 of	 CsA,	 apoptosis	 induction	 by	 ionomycin	 was	 markedly	 suppressed	












were	 retrovirally	 transduced	with	 vectors	 encoding	 either	 NFATc2‐EGFP,	 the	 specific	
inhibitor	of	NFAT	activation	VIVIT,	or	EGFP	control.	The	cells	were	sorted	for	uniform	
expression	of	the	transgene	and	then	either	 left	unstimulated	or	stimulated	with	1	µM	















Interestingly,	 FASLG	was	 also	 established	 as	 the	 first	NFAT	 target	 gene	 in	MKs	 at	 the	
mRNA	 level.79	 However,	 the	 biological	 role	 of	 FASLG	 expression	 by	 NFAT	 in	 MKs,	 is	
largely	unknown.	
Prompted	 by	 our	 observation	 that	 apoptosis	 induction	 in	 MKs	 is	 mediated	 by	 the	
calcineurin/NFAT	 pathway	 (figures	 5.8,	 5.9),	 we	 analyzed	 the	 expression	 of	 FASLG	
protein	in	these	cells.	As	shown	in	figure	5.10,	FASLG	was	undetectable	by	Western	blot	
in	 both	 untreated	 culture‐derived	 primary	 MKs	 and	 CMK	 cells.	 Treatment	 with	
ionomycin	strongly	induced	the	expression	of	FASLG	protein	in	both	cell	types	in	a	time‐
dependent	manner.	Expression	of	FASLG	protein	was	detectable	as	early	as	four	to	six	h	
after	 ionomycin	 stimulation	 and	 followed	 a	 transient	 pattern,	 most	 likely	 because	







calcineurin,	 as	 it	 was	 completely	 blocked	 when	 the	 cells	 were	 pretreated	 with	 CsA	
(figure	 5.10A).	 We	 then	 compared	 the	 expression	 of	 FASLG	 in	 CMK	 cells	 stably	
transduced	with	either	EGFP	(control),	NFATc2	or	VIVIT	(figure	5.10B).	After	ionomycin	
stimulation,	 CMK	 cells	 overexpressing	 NFATc2	 showed	 considerably	 higher	 levels	 of	






Figure	 5.10.	 Activation	 of	 calcineurin/NFAT	 in	 megakaryocytes	 induces	 the	







or	 absence	 of	 CsA.	 Jurkat	 cells	 stimulated	with	 PMA/ionomycin	 for	 4	 h	were	 used	 as	
positive	control.	(B)	CMK	cells	 stably	 transfected	with	NFATc2,	VIVIT	or	EGFP	control	
were	either	left	unstimulated	or	stimulated	for	the	indicated	time	points	(hours)	with	1	




5.2.5 FASLG is located on the cell surface 
 
Although	 transcription	 and	 translation	 of	 FASLG	 is	 central	 for	 its	 appropriate	
expression,	 increasing	 evidence	 shows	 that	 FASLG	 is	 also	 regulated	 at	 a	 post‐
translational	level.		
Cell	surface	FASLG	cleavage	by	matrix	metalloproteinases	is	one	of	the	mechanisms	that	
provides	 an	 efficient	 mechanism	 for	 limiting	 its	 apoptosis‐inducing	 activity.	
Furthermore,	 in	 order	 to	 exert	 its	 pro‐apoptotic	 effect,	 the	 FASLG	 protein	 has	 to	 be	
localized	on	 the	membrane	of	 the	effector	cell	and,	 for	maximum	Fas	receptor	contact	
and	 cell	 death‐inducing	 potency,	must	 be	 localized	within	membrane	 rafts.182,	 183	 	We	
therefore	analyzed	the	localization	of	FASLG	induced	by	ionomycin	treatment	in	MKs	by	
two	 different	 methods	 (figure	 5.11).	 First,	 CMK	 cells	 were	 stained	 with	 an	 antibody	
against	 FASLG	 and	 analyzed	 by	 flow	 cytometry	 (figure	 5.11A).	 An	 increase	 in	
membrane‐bound	 FASLG	 was	 observed	 after	 stimulation	 with	 ionomycin	 in	 the	
presence	 of	 a	 metalloproteinase	 inhibitor	 (MPi),	 which	 prevents	 shedding	 of	 FASLG	
from	 the	 cell	 surface.	 Second,	 we	 investigated	 the	 cellular	 localization	 of	 FASLG	 in	
culture‐derived	 primary	 MKs	 under	 unstimulated	 and	 stimulated	 conditions	 by	
fluorescence	microscopy	(figure	5.11B,	C).	An	anti‐CD61	antibody	was	used	as	a	specific	
























located	on	 the	 cell	 surface.	 (A)	 CMK	 cells	were	 either	 left	 unstimulated	 (grey	 solid	
line)	 or	 stimulated	 with	 1	 µM	 ionomycin	 (black	 fill)	 for	 6	 h	 in	 the	 presence	 of	 a	
metalloproteinase	 inhibitor	 (MPi)	 to	 prevent	 shedding	 of	 FASLG	 from	 the	 surface.	
Expression	of	FASLG	on	the	surface	of	the	cells	was	detected	by	flow	cytometry	using	an	
anti‐FASLG	 antibody.	 Dashed	 line,	 isotype	 control.	 (B)	 Ex	 vivo	 differentiated	 primary	
MKs	were	either	left	unstimulated	or	stimulated	with	1	µM	ionomycin	(Iono)	for	12	h	in	
the	 presence	 or	 absence	 of	 CsA.	 Cytospin	 preparations	 of	 the	 cells	were	 analyzed	 for	













5.2.6 The Fas/FASLG pathway is involved in calcineurin/ NFAT-mediated 
apoptosis induction in megakaryocytes 
 
	As	shown	in	the	previous	experiments,	activation	of	the	calcineurin/NFAT	pathway	in	
MKs	 induces	 apoptosis	 and,	 at	 the	 same	 time,	 cell	 surface	 expression	 of	 the	 pro‐
apoptotic	 FASLG	 protein.	 In	 addition,	 MKs	 constitutively	 express	 Fas,	 the	 FASLG	
receptor.184	 To	 determine	 if	 ionomycin‐induced	 programmed	 cell	 death	 in	 MKs	 was	
mediated	 by	 the	 Fas/FASLG	 pathway,	 we	 tested	 the	 effect	 of	 NOK‐1	 and	 ZB4,	 two	
neutralizing	 antibodies	 directed	 against	 FASLG	 and	 Fas	 respectively.	 Both	 antibodies	
interrupt	 the	 binding	 of	 FASLG	 to	 the	 Fas	 receptor	 and	 thereby	 inhibit	 Fas/FASLG‐
mediated	 signaling.	 Culture‐derived	 primary	 MKs	 (figure	 5.12A,	 B)	 and	 CMK‐NFATc2	
cells	(figure	5.12C)	were	 left	unstimulated	or	 treated	with	1	µM	ionomycin	for	24	h	 in	
the	presence	or	absence	of	NOK‐1	or	ZB4.	The	rate	of	annexin	V‐positive	apoptotic	cells	
was	 monitored	 by	 flow	 cytometry.	 As	 shown	 in	 Fig	 5.12,	 both	 antibodies	 inhibited	









Figure	 5.12.	The	 Fas/FASLG	 pathway	 is	 involved	 in	 calcineurin/NFAT‐mediated	
apoptosis	 induction	 in	megakaryocytes.	 Ex	 vivo	 differentiated	 primary	MKs	 (A,	B)	
and	CMK	cells	overexpressing	NFATc2	(C)	were	either	 left	unstimulated	or	stimulated	
with	 1	 µM	 ionomycin	 (Iono)	 for	 24	 h	 in	 the	 presence	 or	 absence	 of	 neutralizing	
antibodies	 against	 Fas	 (ZB4)	 or	 FASLG	 (NOK‐1),	 as	 indicated.	 The	 apoptosis	 rate	was	
















	In	 addition	 to	 their	 role	 as	producers	of	 platelets,	MKs	 are	known	 to	 express	various	
membrane‐bound	 proteins	 with	 immunomodulatory	 properties	 (e.g.,	 TRAIL,	 CD40	
ligand,	FASLG),	but	the	functional	significance	of	this	phenomenon	is	poorly	understood.	






positive	 CMK	 effector	 cells	 were	 gated	 out	 (figure	 5.14,	 upper	 dot	 blot).	 We	 first	




To	 assess	 the	 effect	 of	 NFAT,	 CMK	 cells	 overexpressing	 NFATc2	 (CMKNFATc2)	 were	
compared	as	effector	cells	to	CMK	cells	expressing	VIVIT	(compare	left	and	right	panels	
in	figure	5.14B).	As	shown	in	figure	5.14B	(panels	i–iii)	and	figure	5.14C,	the	presence	of	
ionomycin‐prestimulated	 CMKNFATc2	 cells	 in	 the	 co‐culture	 induced	 apoptosis	 in	 Jurkat	
cells	at	a	significant	higher	rate	compared	 to	 the	same	cells	without	prestimulation	or	
cells	 prestimulated	 with	 ionomycin	 in	 the	 presence	 of	 CsA.	 In	 contrast,	 ionomycin	
stimulation	in	CMKVIVIT	cells	remained	without	effect	(figure	5.14B,	panels	v–vi,	and	figure	
5.14D),	 suggesting	 that	NFAT	 is	 involved	 in	 this	 process.	 To	 confirm	 that	 induction	of	
apoptosis	 in	 Jurkat	 target	cells	by	stimulated	CMK	effectors	was	mediated	through	the	
Fas/FASLG	pathway,	CMK/Jurkat	co‐cultures	were	performed	in	the	presence	of	either	
ZB4	 (figure	 5.14B,	 panel	 iv)	 or	 NOK‐1	 (figure	 5.14E).	 Both	 antibodies	 completely	
blocked	apoptosis	 induced	 in	 Jurkat	 cells	by	 stimulated	CMK	cells.	These	data	 suggest	














Figure	 5.13.	 Schematic	 representation	 of	 CMK/Jurkat	 co‐cultures.	 CMK	 cells	
(effectors)	were	first	prelabeled	with	CFSE	and	then	remained	either	untreated	or	were	
stimulated	 with	 1	 µM	 ionomycin	 in	 the	 presence	 or	 absence	 of	 CsA	 for	 6	 h.	 After	
washing,	 the	 cells	were	 then	mixed	with	 Jurkat	 cells	 (targets)	 in	 an	 effector‐to‐target	
ratio	(E:	T)	of	10:1.	After	20	h	of	co‐incubation,	 the	cells	were	harvested,	stained	with	














Figure	 5.14.	 Calcineurin/NFAT‐induced	 FASLG	 expression	 in	 megakaryocytes	
induces	 apoptosis	 in	 T	 lymphocytes.	 (A)	 Jurkat	 cells	 (mono‐culture)	 were	 left	
untreated	 or	 treated	 with	 an	 activating	 anti‐Fas	 antibody	 (CH11)	 in	 the	 presence	 of	
absence	of	a	neutralizing	anti	Fas	antibody	(ZB4).	The	apoptosis	rate	was	determined	by	
flow	cytometric	analysis	of	annexin	V‐positive	cells.	(B–E)	CMK	cells	stably	transfected	




rate	 of	 Jurkat	 cells	 was	 analyzed	 by	 flow	 cytometry	 (see	 figure	 5.13	 for	 a	 schematic	
representation	of	 the	experimental	design).	Note	 that	CFSE‐positive	CMK	effector	cells	
were	 gated	 out	 of	 the	 analysis	 (figure	 5.14B,	 top	 dot	 blot).	 Where	 indicated	 (figure	
5.14B,	 panel	 iv;	 figure	 5.14E),	 co‐cultures	 were	 performed	 in	 the	 presence	 of	
neutralizing	 antibodies	 against	 Fas	 (ZB4)	 or	 FASLG	 (NOK‐1).	 (B)	 Dot	 blots	 represent	
Jurkat	 cells	 after	 20	 h	 of	 co‐culture	with	 CMKNFATc2	 or	 CMKVIVIT	 cells,	which	 had	 been	
pretreated	as	indicated	in	the	respective	panel.	(C–E)	Statistical	analysis	of	at	least	three	


























We	 demonstrated	 for	 the	 first	 time	 that	 the	 expression	 of	 FASLG	 protein	 in	 MKs	 is	
induced	by	NFAT	signaling,	 and	we	extended	 this	 finding	 to	a	 functional	 level,	 i.e.,	 the	
induction	 of	 apoptosis	 in	 bystander	 cells	 mediated	 by	 NFATc2‐induced	 FASLG.	 This	
novel	 finding	prompted	us	 to	 look	 for	 further	NFATc2	target	genes	 in	MKs	globally,	 in	
order	to	further	define	the	role	of	NFAT	in	these	cells.	For	this	purpose,	we	performed	






the	 isolation	of	murine	MKs	by	elutriation	or	cell	 sorting	has	 resulted	 in	poor	yield	of	
intact	 cells,	 and	 such	 cell	 populations	 are	 not	 sufficiently	 pure	 which	 limits	 their	
application	 in,	 for	 example,	 RT‐PCR	 analysis	 of	 gene	 expression	 at	 the	mRNA	 level.66	






contaminating	non‐MK	cells,	 the	BM	cell	suspension	was	enriched	 for	 lineage‐negative	
cells	 using	 immunomagnetic	 beads	 conjugated	 to	 an	 anti‐lineage+	mAb	 cocktail	 before	
initiating	 the	ex	vivo	 differentiation	 culture.	 Lineage‐negative	 cells	were	 then	 cultured	
for	3‐4	days	with	100	ng/ml	TPO	to	obtain	an	enriched	population	of	MKs.	Efficiency	of	
the	 differentiation	 process	 was	 examined	 by	 the	 morphology	 of	 the	 cells	 (May‐
Grünwald‐Giemsa	 staining,	 figure	5.15)	 as	well	 as	by	 analysis	of	 surface	 expression	of	







cytoplasm	 in	 immature	 cells	which	 turns	 to	 granulated	 and	 acidophilic	 in	mature	 and	




phase	 was	 removed,	 the	 pellet	 resuspended	 and	 analyzed	 for	 purity	 (>95%)	 and	






Figure	 5.15.	 Differentiation	 and	 isolation	 of	murine	megakaryocytes.	 	 The	 left	
image	illustrates	the	cell	culture	appearance	of	the	 lineage‐negative	fraction	of	murine	
BM	after	2‐3	d	in	the	presence	of	TPO.		Large	cells	represent	immature	and	mature	MKs.		





5.3.2 RNA-sequencing (next generation sequencing) experimental design 
 
Since	NFAT	needs	to	be	activated	in	order	to	translocate	to	the	nucleus	and	bind	to	the	






interested	 in	 comparison	 between	 untreated	 and	 ionomycin‐treated	 murine	 MKs	








Before	 performing	 differential	 expression	 tests,	 sequences	 generated	 from	 RNA‐Seq	
experiment	 should	 be	mapped	 to	 libraries	 of	 known	exons	 in	 known	 transcripts.	 This	
step	is	absent	 in	microarray	expression	analysis.	Moreover,	some	basic	statistical	 tests	
such	 as	 correlation	 of	 samples	 and	 variance	 estimation	 are	 necessary	 to	 evaluate	 the	






Millions	 of	 reads	were	 generated	 by	 single	 end	 sequencing	 from	 24	 cDNA	 libraries	 –








Correlation	 (sample‐to‐sample	 linear	 dependence)	 between	 each	 two	 samples	 was	
calculated	 (figure	5.16).	 "The	 correlation	 coefficient	 ranges	 from	−1	 to	1.	A	 value	of	 1	






all	data	points	lying	on	a		line for	which	Y increases	as X increases.	A	value	of	−1	implies	
that	all	data	points	lie	on	a	line	for	which Y decreases	as X increases.	A	value	of	0	implies	
that	 there	 is	 no	 linear	 correlation	 between	 the	 variables"	 (adapted	 from	 Wikipedia;		
http://en.wikipedia.org/wiki/Pearson_product‐moment_correlation_coefficient).	 Figure	
5.16	shows	the	correlation	coefficient	of	~1	(0.97‐0.99)	calculated	for	all	samples.		The	





Figure	5.16.	Correlation	of	 the	 samples.	Correlation	 plot	 together	with	 coefficients	









To	 check	 the	 dispersion	 among	 the	 replicates,	 variance	 estimation	 was	 performed.	
Typically,	 many	 of	 the	 values	 below	 the	 red	 curve	 are	 underestimates	 of	 the	 true	
dispersions,	so	DESeq	biostatistics	package	uses	the	fitted	values	for	them.	However,	not	
all	values	above	the	red	curve	are	overestimates,	so	the	conservative	choice	 is	to	keep	
them	(instead	of	using	 the	 fitted	values).	Figure	5.17	contains	 the	variance	estimation	
plots	 for	all	conditions	("WT",	 "WTst",	 "KO",	"KOst")	and	 indicates	how	the	expression	
value	of	biological	replicates	are	distributed	(how	far	the	expression	values	lie	from	the	











all	 conditions:	 WT,	 KO,	 WTst,	 KOst.	 Dispersion	 is	 calculated	 by	 the	 square	 of	 the	









To	 test	 for	 differential	 expression,	 we	 did	 the	 following	 comparisons	 among	 four	






First,	 we	 calculated	 the	 number	 of	 significantly	 differentially	 expressed	 genes	 in	
resigDEMK1	and	resigDEMK2,	which	resulted	in	6161	and	22	genes,	respectively.	Then,	
significantly	 differentially	 expressed	 genes	 were	 analyzed	 in	 comparison	 of	 WTst	 vs.	
KOst	(resigDEMK4),	which	resulted	in	592	genes.	
NFAT	is	a	 transcription	 factor,	which	 is	 inactive	without	stimulation	(see	 introduction,	
section	 2.1).	 Genes	 regulated	 by	NFAT	 therefore,	 are	 not	 expected	 to	 be	 expressed	 at	
considerable	 levels	 in	 unstimulated	 samples	 (WT	 and	 KO).	 As	 "genes	 of	 interest"	
therefore	 were	 those	 genes	 considered	 which	 appear	 in	 resigDEMK4	 but	 not	 in	
resigDEMK2,	because	genes	differentially	expressed	between	unstimulated‐WT	and	‐KO	
samples	most	likely	represent	artefacts	(for	example,	unspecific	consequence	of	a	gene	
knockout).	 Finally,	 to	 confirm	 the	 accuracy	 of	 the	 presumed	 “genes	 of	 interest”,	 we	














Figure	 5.18.	 Plots	 of	 the	 significantly	 differentially	 expressed	 (DE)	 genes.	
Differentially	 expressed	 genes	 were	 obtained	 by	 plotting	 "log2	 fold	 change"	 against	
"normalized	mean	expression	level".	Red	dots	represent	significantly	DE	genes.	WT	vs.	
























Table	5.2.	Summary	of	differentially	expressed	genes.	 	 The	DEGs	 column	 contains	
the	number	of	significantly	differentially	expressed	genes	at	the	given	comparison.	The	
second	 part	 of	 the	 table	 (set	 difference)	 lists	 the	 number	 of	 "interesting"	 genes	 that	
appear	in	resigDEMK4	but	not	in	resigDEMK2.		Out	of	these	580	"interesting"	genes,	492	
genes	 ("OK	 genes")	 showed	 the	 same	 behavior	 in	 resigDEMK1	 (i.e.,	were	 upregulated	







5.3.4.1	 Confirmation	 of	 results	 by	 known	 NFATc2	 target	 genes	 in	
Megakaryocytes	
	
In	 order	 to	 confirm	 the	 reliability	 of	 the	 final	 list	 of	 genes,	we	 analyzed	 them	 for	 the	















Figure	 5.20.	 Confirmation	 of	 RNA‐Seq	 data.	 (A)	 DSCR1	 gene	 (gene	 Ensembl	 ID:	
ENSMUSG00000022951)	 appeared	 in	 the	 list	 of	 "interesting	 gene".	 (B)	 Total	 RNA	










                                                                                                                                                                  




of	 492	 genes	 was	 subdivided	 into	 an	 upregulated	 group	 (significantly	 differentially	
expressed	 genes,	which	 are	 upregulated	 by	 the	 activation	 of	 NFATc2,	 i.e.,	 in	WTst	 vs.	
KOst)	and	a	downregulated	group.	For	the	functional	annotation	and	grouping	analysis,	
the	 genes	 were	 annotated	 with	 information	 from	 various	 databases	 in	 order	 to	 find	
common	 features	 among	 the	 genes	 sharing	 similar	 expression	 characteristics.	 The	
annotations	used	were	derived	 from	Gene	Ontology	 (GO),	which	provides	 information	
on	molecular	 function,	 as	well	 as	 from	 various	 pathway	 resources	 for	 information	 on	
involvement	in	biological	signaling	pathways.	Subsequently,	the	gene	list(s)	are	used	for	
database	queries	searching	for	annotations	related	to	functional	categories	or	pathway	
membership.	 In	 addition,	 the	 gene	 lists	 obtained	 are	 compared	 to	 known	 targets	 of	




more	 extensive	 set	 of	 pathways	 and	 biological	 categories.	 In	 the	 present	 analysis,	 the	
upregulated	 gene	 list	 exhibits	 a	 large	 number	 of	 highly	 significant	 associations	 with	
broad	 categories	 such	 as	 innate	 immunity,	 inflammation,	 T‐cell	 immunity,	 B‐cell	
immunity	 and	 with	 more	 specific	 pathways	 like	 cytokine	 signaling,	 NF‐κB	 signaling,	
death‐receptor	signaling,	the	IL‐4,	IL‐6,	wnt	and	TGF‐ß	pathways	(table	5.3).	By	contrast,	
the	 (much	 smaller)	 list	 of	 downregulated	 genes	 does	 hardly	 show	 any	 meaningful	













































Further	 analysis	 on	 biological	 pathways	 indicated	 that	 while	 the	 majority	 of	 the	
enriched	categories	are	 indicative	of	an	actively	ongoing	 immune	response	(or	at	 least	
an	activated	state	of	various	immune	cells),	there	are	a	few	enriched	categories	without	
a	direct	 link	 to	 the	 immune	system.	Among	 them	 is	 a	10‐fold	enrichment	of	 the	nitric	
oxide	(NO)	biosynthesis	gene,	Nos2	(encoding	the	inducible	nitric	oxide	synthesis	iNOS).	
Nos2	is	seen	on	the	top	of	the	gene	list	of	enriched	categories	(table	5.4)	that	was	sorted	
by	 the	 transcriptional	 effect	 of	 stimulation	 in	 the	 WT	 cells.	 Ch25h	 (encoding	 a	
cholesterol	 hydroxylase)	 and	 Arg1	 (encoding	 arginase)	 were	 also	 among	 the	 top‐
induced	genes.	Interestingly	both	Nos2	and	Arg1	are	implicated	in	NO	signaling	and	so	















































6.1	 Lack	of	 the	 transcription	 factor	NFATc2	 in	hematopoietic	 stem	
cells	results	in	profound	hematological	abnormalities	in	mice	
	
NFATc2	 has	 been	 shown	 to	 be	 expressed	 in	 hematopoietic	 stem	 cells.	 Therefore,	




We	 have	 previously	 shown	 that	 aged	 mice	 lacking	 the	 transcription	 factor	 NFATc2	
develop	BM	hypoplasia,	 anemia,	 thrombocytopenia	 and	 extramedullary	hematopoiesis	
in	spleen	and	liver.84,	106	The	proliferation	and	differentiation	of	NFATc2‐deficient	HSCs	
ex	vivo,	however,	was	found	to	be	intact.	In	this	study	we	aimed	to	address	the	question	
whether	 the	 disturbed	 hematopoiesis	 in	 NFATc2‐deficient	 mice	 was	 caused	 by	 the	
hematopoietic	or	the	stroma	component	of	the	BM	hematopoietic	niche.	Therefore,	we	
performed	 reciprocal	 transplantation	 experiments	 in	 which	 NFATc2‐/‐	 HSCs	 were	
transplanted	 into	 WT	 mice	 and	 vice	 versa.	 Subsequently,	 post‐transplantation	





At	 present,	 BM	 and	 peripheral	 blood	 hematopoietic	 stem	 cell	 transplantation	 are	
considered	to	be	potentially	 therapeutic	ways	 for	a	variety	of	BM	disorders.	Following	
transplantation,	 HSCs	 are	 able	 to	 reconstitute	 the	 recipient.186	 However,	 the	 use	 of	
whole	BM	as	 a	 source	of	 stem	cells	 includes	 the	 risk	of	 transplantating	 contaminating	
stroma	cells,	which	for	our	experimental	purposes	was	not	suitable.89	







common	 myeloid	 progenitors,	 CMP)	 and	 repopulate	 long‐term	 blood‐lineage	 in	
irradiated	 recipients.166,	 168	 Thus,	 we	 employed	 LSK	 cells	 for	 the	 transplantation	
experiments.	
	
6.1.2	 NFATc2	 deficiency	 in	 HSCs	 leads	 to	 hematological	 and	 stroma	
abnormalities	
	
In	 the	 current	 study,	we	demonstrate	 that	 transplantation	 of	NFATc2‐/‐	HSCs	 into	WT	
mice	 leads	 to	 the	 induction	 of	 hematologic	 abnormalities,	 similar	 to	 those	which	 had	
been	 observed	 in	 (non‐transplanted)	 aged	 KO	 mice.	 The	 hematologic	 abnormalities	
were	significant	with	respect	to	the	induction	of	anemia	and	thrombocytopenia	as	well	
as	extramedullary	hematopoiesis	in	spleen	and	liver.	In	addition,	KO	mice	transplanted	
by	WT	HSCs	 demonstrated	 a	 remarkable	 reduction	 in	 the	 hematologic	 abnormalities,	
which	had	been	observed	in	non‐transplanted	KO	mice.	
Hitherto,	 it	 had	 been	 established	 that	 NFATc2	 is	 expressed	 in	 HSCs	 and	 that	 its	
expression	 is	 maintained	 during	 megakaryopoiesis.78,	 79	 In	 contrast,	 it	 had	 not	 been	
described	 as	 a	 crucial	 transcription	 factor	 required	 for	 hematopoiesis.	 In	 mice	 with	
NFATc2	deficiency,	the	hematopoietic	organs	(blood,	BM	and	spleen)	are	abnormal,	but	
the	differentiation	potential	of	HSCs	is	preserved.	
Even	 though	a	 lot	of	evidence	 indicates	 its	 importance	 in	 the	 lifespan	of	HSCs,	 the	BM	
niche	 is	 not	 the	 only	 mechanism	 for	 HSC	 regulation.	 The	 stem	 cell	 itself	 has	 crucial	
impact.	 Fetal	 liver‐derived	 HSCs,	 for	 instance,	 have	 been	 shown	 to	 exhibit	 a	 more	
efficient	regeneration	potential	than	similar	cells	from	adult	BM	when	transplanted	into	





partly	 compensated	 by	 extramedullary	 hematopoiesis	 in	 spleen	 and	 liver.	 The	
observation	 from	 the	 current	 study,	 in	 which	 transplantation	 of	 HSCs	 from	WT	mice	








cell	 cycle	 and	proliferation.	A	 large	number	of	 genes	 associated	with	 cell	 proliferation	
and	apoptosis	are	induced	by	NFAT.190	In	some	systems,	NFATc2	appears	to	negatively	
control	cell	proliferation,18,	31,	191	since	its	deficiency	(despite	the	presence	of	other	NFAT	





Of	 note,	 the	 hematopoietic	 abnormalities	 induced	 by	 NFATc2‐deficient	 HSCs	 are	
markedly	 apparent	 in	 erythroid	 and	 megakaryocytic	 lineages,	 consistent	 with	 the	
anemia	 and	 thrombocytopenia	 observed	 in	 the	 peripheral	 blood	 of	 NFATc2‐/‐	 mice.		
These	 abnormalities	 are	 rescued	 by	 transplantation	 of	 WT	 HSCs.	 Therefore,	 one	 can	
speculate	 that	 NFATc2	 has	 a	 stronger	 impact	 on	 megakaryocyte‐erythroid	 lineage	
commitment	than	on	other	myeloid	lineages	such	as	granulocyte‐macrophage	lineages.	
However,	 NFATc2	 activation	 is	 not	 required	 for	 erythrocyte	 and	MK	 differentiation.84	
Therefore,	 an	 attractive	 hypothesis	 may	 be	 that	 NFATc2	 mediates	 cell	 cycle	 and	
proliferation	 of	 erythro‐megakaryocytic	 committed	 lineages	 rather	 than	 of	 other	
myeloid	lineages	or	of	lymphocytes.				
Nevertheless,	 the	 phenotype	 observed	 in	 NFATc2‐deficient	 mice	 does	 not	 exclude	 an	
aberrant	 HSC‐stroma	 crosstalk.	 One	 of	 the	 possible	 mechanisms	 might	 be	 perturbed	
homing	caused	by	the	absence	of	NFATc2.	In	order	to	efficiently	establish	hematopoiesis	
after	transplantation,	HSCs	must	home	into	hematopoietic	organs,	especially	the	BM.192,	
193	 We	 tested	 our	 hypothesis	 by	 performing	 homing	 assays,	 in	 which	 hematopoietic	
stem/progenitor	 (lineage‐negative)	 cells	 of	 the	 BM	 were	 isolated	 and	 labeled	 with	 a	
viable	dye	(CFSE).	This	dye	allows	the	detection	of	fluorescent	cells	for	up	to	seven	cell	
divisions,	which	is	adequate	for	the	time	of	homing	(~20	h)	in	our	system.	The	results	
revealed	 no	 differences	 between	 WT	 and	 KO	 HSC	 in	 number	 of	 donor‐derived	
hematopoietic	 stem/progenitor	 cells	 homing	 to	 the	 marrow	 of	 recipient	 mice	 (figure	
5.6).	 These	 results	 could	be	 confounded	by	 the	 fact	 that	 cells	 passing	 through	 the	BM	





suggest	 that	 the	 extreme	 adhesion	 capacities	 of	 injected	 stem	 cells	 force	 them	 to	
immediately	 leave	 the	 central	 vein	 and	 reach	 the	 BM	 niche	 within	 a	 few	 hours.194	
Therefore,	in	the	current	experiment,	we	chose	20	h	after	injection	as	the	time	point	for	
the	evaluation	of	homing	cells	in	BM.	Secondly,	we	found	clearance	of	labeled	cells	from	
the	 peripheral	 blood	 of	 the	 transplanted	 mice	 at	 this	 time	 point,	 which	 declines	 the	




verify	 the	 appropriate	 time	 of	 detection	 in	 this	 experiment.	 Our	 results	 suggest	 that	
homing	of	NFATc2‐deficient	HSCs	is	normal.	Nevertheless,	due	to	the	limitations	of	the	
experimental	systems	used,	homing	deficiency	cannot	be	excluded	as	mechanism	of	the	





Homing	 is	 a	 highly	 regulated	 process,93	 in	 which	 the	 expression	 of	 cell	 adhesion	
molecules	 and	 the	 impact	 of	 intrinsic	 and	 extrinsic	 pathways	 which	 mediate	 the	
interaction	 of	 HSCs	 with	 the	 niche	 has	 to	 be	 considered.	 HSC	 engraftment	 has	 been	
shown	 to	 take	place	 in	perivascular	 spaces,195,	 196	which	draws	 the	 focus	on	a	 role	 for	
molecules	 such	 as	 angiopoietin‐1	 receptor	 Tek	 and	 adhesion	molecule	 Integrin‐ß1	 in	
maintenance	and	homing	of	transplanted	HSCs.197	The	expression	of	adhesion	molecules	
or	chemokine	receptors	 in	NFATc2‐deficient	HSC	has	not	been	studied	so	 far	 in	detail,	
but	 may	 be	 a	 focus	 for	 further	 experiments	 in	 the	 future.	 Finally,	 experiments	
monitoring	 the	 proliferation	 of	 transplanted	 HSCs	 in	 vivo	 are	 essential	 to	 be	 also	
considered	in	future	plans.	
Previously,	 we	 have	 shown	 that	 the	marrow	 of	 aged	 KO	mice	 exhibit	 intramedullary	
sclerosis,	 although	 to	 a	 variable	 extent.	The	next	 interesting	question	was	whether,	 in	
addition	to	their	impact	on	hematopoiesis,	donor‐derived	HSCs	are	able	to	transfer	their	
phenotype	to	the	BM	stroma	as	well.	Transplantation	of	KO	HSCs	to	WT	recipients	was	
found	 to	modify	 the	marrow	 structure.	We	 showed	 that	WT	mice	 transplanted	by	KO	





the	 case	 in	 the	marrow	of	KO	mice	 receiving	KO	HSCs	 (KOKO)	 but	 not	 in	WT	mice	
transplanted	by	WT	HSCs	(WTWT)	(figure	5.3	D,	E).	This	phenomenon	was	however	
incomplete.	 Though	 in	 some	 cases	 of	 KOWT	 mice	 a	 significant	 myelofibrosis	 and	
formation	of	trabeculae	is	observed,	in	others	either	the	modifications	were	moderate	or	
were	not	observed.	We	 reasoned	 that	 these	 symptoms	are	 apparently	 cumulative	 and	
can	be	detected	in	higher	ages.	
This	 phenotype	 of	 NFATc2‐/‐	 mice	 exhibits	 a	 noticeable	 resemblance	 to	 human	
myelofibrosis	(WHO2008:	primary	myelofibrosis).	Myelofibrosis	is	a	myeloproliferative	
disease	 in	 which	 the	 proliferation	 of	 an	 abnormal	 type	 of	 BM	 stem	 cells	 leads	 to	
thrombocytopenia,	 secondary	 intramedullary	 collagen	 fibrosis,	 splenomegaly	 and	
occurrence	 of	 extramedullary	 hematopoiesis.	 To	 date,	 the	mechanisms	 underlying	 the	
secondary	marrow	 changes	 are	 not	 completely	 understood.106,	 198	Mouse	models	with	
overexpression	 of	 TPO	 (TPOhigh	mice)	 or	 low	 expression	 of	 GATA‐1	 (GATA‐1low	mice)	
have	 also	 been	 shown	 to	 exhibit	 myelofibrosis.	 In	 these	 animals,	 a	 significant	
contribution	 of	 transforming	 growth	 factor‐beta	 1	 (TGF‐ß1)	 originating	 from	
hematopoietic	 cells	 was	 found	 to	 induce	 marrow	 fibrosis.	 Other	 factors,	 including	
osteoprotegerin	 (OPG),	 basic	 fibroblast	 growth	 factor	 (bFGF),	 platelet‐derived	 growth	
factor	(PDGF)	and	vascular‐endothelial	growth	factor	(VEGF)	have	also	been	implicated	
in	 mediating	 osteosclerosis,	 fibrosis	 and	 angiogenesis	 in	 this	 disease.	 It	 is	 currently	
assumed	that	various	cytokine	families,	notably	TGF‐ß,	are	associated	with	alterations	in	
MKs.199‐201	 Since	 TPO	 (extrinsically)	 and	 GATA‐1	 (intrinsically)	 both	 control	 MK	
differentiation,	 the	 development	 of	 myelofibrosis	 in	 above‐mentioned	 mouse	 models	
(TPOhigh	 and	 GATA‐1low)	 is	 the	 result	 of	 high	 TGF‐ß	 levels	 originating	 from	 MK	




expression	 of	 certain	 genes	 (e.g.	 IL‐4,	 IL‐5	 and	 IL‐13)	 in	 Th2	 (T	 helper	 2)	 and	 mast	
cells.202	 A	 crosstalk	 of	 NFAT	 and	 GATA‐1	 could	 also	 be	 illustrated	 in	 patients	 with	
Down's	 syndrome,	 in	 which	 MK	 dysfunction	 might	 be	 the	 consequence	 of	 the	






and	 GATA‐1	might	 have	 roles	 in	 the	 transcriptional	 regulation	 of	 hematopoietic	 cells	
which	themselves	can	influence	the	stroma	compartment	of	the	BM	as	well.	
At	present,	allogenic	stem	cell	transplantation	is	considered	as	one	of	the	most	efficient	
treatments	 for	 the	 patients	 with	myelofibrosis.203,	 204	 	 An	 interesting	 outcome	 of	 this	
study	also	reveals	that	KO	mice	harboring	myelofibrosis	are	at	least	in	part	rescued	by	
WT‐derived	 HSCs	 (WTKO).	 Conversely,	 myelofibrosis	 is	 induced	 in	 WT	 mice	 by	
transplanting	KO	HSCs	(KOWT).			
These	 findings	 should	promote	more	 investigation	 in	 the	 transcriptional	 regulation	 of	
NFATc2,	 particularly	 in	 the	 erythro‐megakaryocytic	 lineage.	 Of	 particular	 interest	
apparently	are	MKs	since	these	cells	are	involved	in	a	number	of	diseases,	for	instance	



























Studies	 in	 MKs	 are	 complicated	 by	 the	 problem	 of	 their	 low	 abundance	 in	 the	 BM	
(~0.5%)	 and	 the	 difficulties	 in	 obtaining	 sufficient	 numbers	 for	 experiments.185,	 205	
Moreover,	 MKs	 isolated	 by	 these	 methods	 are	 not	 sufficiently	 pure	 and	 intact.	
Researchers	 have	 overcome	 these	 problems	 either	 by	 employing	megakaryocytic	 cell	
lines	or	by	differentiating	MKs	ex	vivo	out	of	their	progenitor	cells.	Megakaryocytic	cell	
lines	 (for	 example,	 CMK,	Meg‐01,	M‐07,	 K562)	 provide	 a	 unique	 opportunity	 to	 study	
MKs.205,	206		However,	they	are	leukemic	cells	with	a	modified	karyotype	and	represent	
an	 immature	 state	 of	 MKs.	 Therefore,	 the	 physiological	 significance	 of	 any	 finding	 in	
these	 systems	 needs	 to	 be	 confirmed	 in	 primary	 cells.	 Thus,	 in	 addition	 to	
megakaryocytic	cell	 lines,	we	considered	it	important	to	confirm	our	principal	findings	
in	 culture‐derived	 primary	 MKs	 (ex	 vivo‐differentiated	 MKs).	 	 The	 availability	 of	
thrombopoietin	 (TPO),	 a	 cytokine	 that	 stimulates	 megakaryopoiesis	 enabled	 us	 to	





6.2.1	 NFAT	 regulates	 inducible	 FASLG	 protein	 expression	 in	
megakaryocytes	
	
In	 the	 present	 study,	 we	 identify	 the	 phosphatase	 calcineurin	 and	 the	 transcription	
factor	NFAT	as	part	of	a	calcium‐dependent	signal	transduction	pathway	that	is	central	
for	 inducible	 gene	 expression	 in	 MKs.	 From	 earlier	 studies,	 it	 was	 known	 that	 MKs	
express	 both	 calcineurin	 and	NFAT	 proteins,	 and	 that	 the	 expression	 of	 NFAT	 during	
megakaryopoiesis	was	regulated	in	a	lineage‐specific	manner.78,	79	Neither	activation	of	
calcineurin	nor	of	NFAT,	however,	proved	to	be	necessary	for	the	differentiation	of	MKs	









descriptive	 to	 a	 functional	 level.	 We	 demonstrate	 that	 activation	 of	 the	
calcineurin/NFAT	 pathway	 in	 MKs	 induces	 expression	 of	 the	 FASLG	 protein.	
Immunoblot	 analysis	 revealed	 that	 FASLG	protein,	 in	 stimulated	 ex	vivo	 differentiated	
MKs	as	well	as	in	transfected	megakaryocytic	CMK	cells,	was	detected	within	hours	and	









29	 KDa).	 It	 has	 been	 shown	 that	 sFASLG	 is	 generated	 by	 proteolytic	 cleavage	 of	
membranous	FASLG	by	matrix	metalloproteinases.207	Tanaka	et	al.	have	demonstrated	






induction	 of	 apoptosis.	 Immunofluorescence	 staining	 of	 FASLG	 demonstrates	 the	
accumulation	 of	 FASLG	 protein	 in	 the	 proximity	 or	 on	 the	membrane	 of	mature	MKs	
when	 the	 calcineurin/NFAT	 pathway	 is	 activated.182,	 183	 These	 findings	 raised	 the	













and	receive	 their	genetic	repertoire	 from	their	MK	precursors,	 it	had	to	be	considered	
that	 FASLG	 expression	 in	 MKs	 may	 serve	 the	 sole	 purpose	 to	 transfer	 it	 to	 their	
progeny.126,	 127	 In	addition,	platelets	express	biologically	active	FASLG	on	 their	surface	
which	is	able	to	induce	apoptosis	in	Fas‐positive	cells,	thus	it	was	crucial	to	investigate	
whether	NFAT‐induced	FASLG	protein	in	MKs	is	able	to	exert	biological	activity	as	well.	
One	 of	 the	 main	 findings	 of	 our	 study	 suggests	 that	 FASLG	 expression	 in	 MKs	 is	 of	
intrinsic	biological	significance	for	these	cells.	First,	transcription	of	the	FASLG gene	in	




Of	note,	as	we	demonstrate	 in	this	study,	 the	propensity	of	MKs	to	 induce	apoptosis	 is	
not	a	constitutive	characteristic	of	these	cells,	but	requires	prior	stimulation	with	agents	
that	 increase	 the	 intracellular	 calcium	 to	 levels	 sufficient	 to	 activate	 the	




the	 respective	microenvironment.	 Collagen	 (an	 extracellular	matrix	protein	present	 in	
the	BM)	as	well	 as	 thrombin	are	possible	 candidates,	 as	 treatment	of	MKs	with	either	
agent	is	able	to	induce	activation	of	the	calcineurin/NFAT	pathway	in	vitro	and	regulates	
proplatelet	 formation.143	 Furthermore,	 the	majority	of	MKs	 spend	 their	 lifetime	 in	BM	
until	 they	undergo	apoptosis	and	release	platelets	 into	the	blood	stream.	Collagen,	 the	
main	component	of	connective	tissue,	is	abundantly	found	in	the	extracellular	matrix	of	
the	 BM	 microenvironment	 and	 blood	 vessels,	 thus	 it	 is	 possible	 that	 this	 protein	
functions	as	physiological	ligand	for	MK	stimulation.		








investigation.	 Practically,	 activation	 of	 the	 Fas/FASLG	 pathway	 between	 MKs	 would	
require	that	they	are	 located	in	close	proximity	to	each	other.	Considering	their	rarity,	
this	is	unlikely	to	occur	during	megakaryopoiesis.	However,	it	has	been	shown	that	some	
cell	 types	 express	 both	 Fas	 and	 FASLG	 concurrently	 that	 could	 potentially	 lead	 to	
autocrine	 cell	 death.211,	 212	 After	 conclusion	 of	 their	 maturation,	 MKs	 are	 known	 to	
migrate	within	the	BM	to	blood	vessels,	where	they	release	their	platelets	in	a	process	
called	 proplatelet	 formation.	 As	 an	 intriguing	 hypothesis,	 MK	 apoptosis	 under	 these	
circumstances	might	be	induced	by	other,	co‐migrating	MKs,	which	had	been	activated	
within	the	BM	vascular	niche	to	upregulate	expression	of	FASLG	on	their	membrane.		
It	 has	 to	 be	 noted,	 however,	 that	 blocking	 antibodies	 against	 Fas	 and	 FASLG	 are	 only	




inhibiting	 calcineurin	 activation.213	 Overexpression	 of	 Bcl‐2	 for	 instance,	 results	 in	





system.	 It	 is	 now	obvious	 that	 the	 cells	 in	 the	BM	are	not	 only	 connected	 in	 terms	of	
proximity	but	by	functionality,	and	it	is	increasingly	recognized	that	MKs,	despite	their	
rarity,	 exert	 biological	 functions	 independent	 from	 their	 role	 as	 platelet	 producers.	
Several	 studies,	 for	 example,	 show	 that	 they	 are	 involved	 in	 the	maintenance	 of	 bone	
homeostasis.217‐219	 They	 produce	 cytokines	 that	 induce	 fibrosis	 in	 the	 BM	 and	 other	
organs	 including	 spleen	 and	 lung.220‐222	 Growth	 factors	 and	 cytokines	 such	 as	 PDGF,	
bFGF	and	TGF‐ß	which	are	produced	by	MKs,	 are	 found	 to	be	 the	major	mediators	of	
increased	reticulin	fibers	in	myelofibrosis	disorders.221,	223	Under	certain	circumstances,	







Hence,	MKs	 interact	with	 their	microenvironment,	 but	 their	 cellular	 counterparts	 and	
the	mechanisms	of	cellular	interaction	are	incompletely	understood.	In	this	respect,	our	
study	provides	interesting	findings.	The	physiological	relevance	of	Fas/FASLG‐mediated	





































Though	 the	 list	of	genes	which	were	dependent	on	 the	presence	of	NFATc2,	was	clear	
and	significant,	at	 the	same	time	 it	was	quite	unexpected.	An	 interesting	finding	was	a	
strong	and	broad	immune‐activation	phenotype	regulated	by	NFATc2,	going	along	with	
the	strong	induction	of	many	genes	involved	in	various	aspects	of	the	immune	response.	
While	 such	 an	 immune‐stimulatory	 effect	would	have	been	 expected	 as	 a	 response	 to	
NFAT	stimulation,	the	genes	involved	in	the	observed	response	do	hardly	overlap	with	
the	canonical	NFAT	target	genes.	Interestingly,	the	pathways	induced	by	the	treatment	





the	 top	 of	 the	 gene	 list	 that	 were	 sorted	 by	 the	 transcriptional	 effect	 of	 ionomycin‐
stimulation	 in	 the	WT	 cells.	 Interestingly,	 four	 out	 of	 six	most	 strongly	 induced	 genes	
have	 a	 role	 in	 NO	 biosynthesis	 from	 arginine.	 This	 pathway	 is	 known	 to	 play	 an	
important	role	in	macrophages,	however,	the	upregulation	factor	of	the	NO	biosynthesis	
genes	 is	 much	 higher	 than	 that	 of	 most	 other	 macrophage‐specific	 markers,	 which	
suggests	that	this	pathway	might	be	important	in	MKs.		
The	 current	 findings	 contribute	 a	 novel	 understanding	 of	 NFAT	 transcriptional	
regulation	in	mature	MKs.	However,	data	validation	by	quantitative	PCR	or	PCR‐array	as	
well	 as	 by	 functional	 assays	 of	 differentially	 expressed	 genes	 is	 still	 necessary	 and	
should	 be	 scheduled	 for	 future	 studies.	 Furthermore,	 these	 data	 represent	 a	 useful	









The	 NFAT	 transcription	 factors	 are	 primarily	 known	 for	 their	 central	 role	 in	
transcriptional	 regulation	 of	 lymphocytes.	 Recently,	 the	 family	 member	 NFATc2	 has	
been	shown	to	be	expressed	 in	hematopoietic	stem	cells	as	well	as	 in	specific	myeloid	
cell	 types,	 especially	 in	MKs.	 The	 function	 of	 this	 transcription	 factor	 in	 this	 context,	
however,	 was	 unknown.	 The	 aim	 of	 the	 present	 work	 was	 to	 contribute	 to	 the	
understanding	of	the	role	of	NFAT	in	hematopoietic	cells,	with	a	particular	focus	on	MKs.	
	
We	 show	 that	 lack	 of	 NFATc2	 in	 hematopoietic	 stem	 cells	 results	 in	 perturbed	
hematopoiesis	 in	 mice,	 namely	 BM	 hypoplasia,	 peripheral	 blood	 cytopenia	 and	
extramedullary	hematopoiesis.	Our	results	point	to	disrupted	interaction	of	the	NFATc2‐
deficient	 stem	 cell	 with	 its	 BM	 hematopoietic	 niche.	 One	 possible	 mechanism	 is	 an	
inefficient	 homing	 capability	 of	 HSCs,	 but	 this	 could	 not	 be	 experimentally	 proven.	
Alternative	 possibilities	 include	 cell‐intrinsic	 mechanisms	 such	 as	 cell	 cycle	 or	
proliferation,	but	the	ex	vivo	characteristics	of	NFATc2‐/‐	seem	to	be	normal.		
	
While	 the	 activation	 of	 NFATc2	 has	 shown	 to	 be	 dispensable	 for	 megakaryocytic	
differentiation,	 previous	 studies	 had	 suggested	 that	 NFATc2	 plays	 a	 role	 in	 the	
regulation	of	 inducible	 gene	 expression	 in	mature	MKs.	Here,	we	demonstrate	 for	 the	
first	 time	 that	 expression	 of	 the	 Fas	 ligand	 protein	 in	 MKs	 occurs	 in	 an	 inducible,	
calcineurin/NFAT‐dependent	 manner,	 and	 is	 transported	 to	 the	 MK	membrane.	 Most	
importantly,	we	prove	that	Fas	ligand	protein	induced	by	NFAT	signaling	is	biologically	
active	and	able	to	induce	apoptosis	in	Fas‐bearing	bystander	cells.		
Finally,	 we	 have	 identified	 by	 RNA	 sequencing	 analysis	 of	 NFATc2‐expressing	 and	 ‐
deficient	 cells	 the	 entire	 set	 of	 genes	which	 is	 induced	by	NFATc2	 in	 stimulated	MKs.	










biological	 role	 in	 hematopoiesis.	 Lack	 of	 NFATc2	 in	 hematopoietic	 stem	 cells	
leads	to	hematological	and	osteogenic	abnormalities	in	mice.	
	
 Hematopoietic	 stem	 cells	 with	 NFATc2	 deficiency	 are	 able	 to	 transfer	 the	
phenotype	of	aged	NFATc2‐deficient	mice	to	wild	type	mice.	
	




might	 be	 exploited	 as	 therapeutic	 target	 for	 the	 development	 of	 new	drugs	 for	
treatment	of	hematological	disorders	in	the	future.	
	
 NFATc2	 is	 a	 transcriptional	 regulator	 of	 gene	 expression	 in	 mature	
megakaryocytes.	
	
 Activation	 of	 the	 calcineurin/NFAT‐pathway	 leads	 to	 the	 expression	 of	 the	 Fas	
Ligand	gene	and	subsequently,	its	protein.		
	
 Fas	 Ligand	 protein	 induced	 by	 the	 activation	 of	 calcineurin/NFAT	 pathway	 is	
biologically	 functional	 as	 it	 is	 transferred	 to	 the	membrane	 of	megakaryocytes	
and	is	able	to	induce	programmed	cell	death	in	Fas‐positive	bystander	cells.	
	








 Further	 studies	 should	 aim	 to	 investigate	 the	 regulatory	 role	 of	 NFAT	 in	
hematopoiesis,	 in	 hematopoietic	 cells	 of	 various	 lineages	 (specifically	
megakaryocytes)	and	the	stroma	components	of	the	hematopoietic	niche.	
	
 The	 expression	 profile	 of	 genes	 regulated	 by	 NFATc2	 in	 stimulated	
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